General References


R Yang X, Pfeiffer RM, Goldstein AM. Influence of glutathione-S-transferase (GSTM1, GSTP1, GSTT1) and cytochrome p450 (CYP1A1, CYP2D6) polymorphisms on numbers of basal cell carcinomas (BCCs) in families with the naevoid basal cell carcinoma syndrome. J Med Genet 2006; 43:16.

Raaska K, Neuvonen PJ. Serum concentrations of clozapine and N-desmethylclozapine are unaffected by the potent CYP3A4 inhibitor itraconazole. Eur J Clin Pharmacol 1998; 54:167-70.

Raaska K, Niemi M, Neuvonen M, Neuvonen PJ, Kivistö KT. Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole. Clin Pharmacol Ther 2002; 72:362-9.

Rabe B, Chalaris A, May U et al. Transgenic blockade of interleukin 6 transsignaling abrogates inflammation. Blood 2008; 111:1021-8.

Raber J, Wong D, Yu G-Q et al. Apolipoprotein E and cognitive performance. Nature 2000; 404:352-4.

Rabiet MJ, Furie BC, Furie B. Molecular defect of prothrombin Barcelona. Substitution of cysteine for arginine at residue 273. J Biol Chem 1986; 261:15045-8.

Rabik CA, Maryon EB, Kasza K, Shafer JT, Bartnik CM, Dolan ME. Role of copper transporters in resistance to platinating agents. Cancer Chemother Pharmacol 2009; 64:133-42.

Race JE, Grassl SM, Williams WJ, Holtzman EJ. Molecular cloning and characterization of two novel human renal organic anion transporters (hOAT1 and hOAT3). Biochem Biophys Res Commun 1999; 255:508-14.

Racine R, Grandcolas L, Grison S et al. Cholesterol 7alpha-hydroxylase (CYP7A1) activity is modified after chronic ingestion of depleted uranium in the rat. J Steroid Biochem Mol Biol 2010; 120:60-6.

Rachalski A, Alexandre C, Bernard JF et al. Altered sleep homeostasis after restraint stress in 5-HTT knock-out male mice: a role for hypocretins. J Neurosci 2009; 29:15575-85.

Radel M, Vallejo RL, Iwata N et al. Haplotype-based localization of an alcohol dependence gene to the 5q34 {gamma}-aminobutyric acid type A gene cluster. Arch Gen Psychiatry 2005; 62:47-55.

Rademaker M. Do women have more adverse drug reactions? Am J Clin Dermatol 2001; 2:349-51.

Rademakers R, Cruts M, Dermaut B et al. Tau negative frontal lobe dementia at 17q21: significant finemapping of the candidate region to a 4. 8 cM interval. Mol Psychiatry 2002; 7:1064-74.

Rademakers R, Dermaut B, Peeters K et al. Tau (MAPT) mutation arg406trp presenting clinically with Alzheimer’s disease does not share a common founder in western Europe. Hum Mutat 2003; 22:409-11.

Radisky DC, Levy DD, Littlepage LE et al. Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature 2005; 436:123-27.

Rådmark O, Samuelsson B. Regulation of the activity of 5-lipoxygenase, a key enzyme in leukotriene biosynthesis. Biochem Biophys Res Commun 2010; 396:105-10.

Rådmark O, Werz O, Steinhilber D, Samuelsson B. 5-Lipoxygenase: regulation of expression and enzyme activity. Trends Biochem Sci 2007; 32:332-41.

Radpour R, Rezaee M, Tavasoly A, Solati S, Saleki A. Association of long polyglycine tracts (GGN repeats) in exon 1 of the androgen receptor gene with cryptorchidism and penile hypospadias in Iranian patients. J Androl 2007; 28:164-9.

Rae JM, Johnson MD, Lippman ME, Flockhart DA. Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. J Pharmacol Exp Ther 2001; 299:849-57.

Rae JM, Sikora MJ, Henry NL et al. Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients. Pharmacogenomics J 2009; 9:258-64.

Rae JM, Soukhova NV, Flockhart DA, Desta Z. Triethylenethiophosphoramide is a specific inhibitor of cytochrome P450 2B6: implications for cyclophosphamide metabolism. Drug Metab Dispos 2002; 30:525-30.

Raeissi SD, Guo Z, Dobson GL, Artursson P, Hidalgo IJ. Comparison of CYP3A activities in a subclone of Caco-2 cells (TC7) and human intestine. Pharm Res 1997; 14:1019-25.

Raeissi SD, Hidalgo IJ, Segura-Aguilar J, Artursson P. Interplay between CYP3A-mediated metabolism and polarized efflux of terfenadine and its metabolites in intestinal epithelial Caco-2 (TC7) cell monolayers. Pharm Res 1999; 16:625-32.

Raffa RB, Stone DJ Jr. Unexceptional seizure potential of tramadol or its enantiomers or metabolites in mice. J Pharmacol Exp Ther 2008; 325:500-6.

Raftogianis RB, Her C, Weinshilboum RM. Human phenol sulfotransferase pharmacogenetics: STP1 gene cloning and structural characterization. Pharmacogenetics 1996; 6:473-87.

Raghuveer K, Senthilkumaran B, Sudhakumari CC et al. Dimorphic expression of various transcription factor and steroidogenic enzyme genes during gonadal ontogeny in the air-breathing catfish, Clarias gariepinus. Sex Dev 2011; 5:213-23.

Ragia G, Nikolaidis E, Tavridou A et al. Renin-angiotensin-aldosterone system gene polymorphisms in coronary artery bypass graft surgery patients. J Renin Angiotensin Aldosterone Syst 2010; 11:136-45.

Ragin CC, Langevin S, Rubin S, Taioli E. Review of studies on metabolic genes and cancer in populations of African descent. Genet Med 2010; 12:12-8.

Ragueneau-Majlessi I, Levy RH, Bergen D et al. Carbamazepine pharmacokinetics are not affected by zonisamide: in vitro mechanistic study and in vivo clinical study in epileptic patients. Epilepsy Res 2004; 62:1-11.

Ragunathan N, Dairou J, Sanfins E et al. Cadmium alters the biotransformation of carcinogenic aromatic amines by arylamine N-acetyltransferase xenobiotic-metabolizing enzymes: molecular, cellular, and in vivo studies. Environ Health Perspect 2010; 118:1685-91.

Rahman MM, Kipreos ET. The specific roles of mitotic cyclins revealed. Cell Cycle 2010; 9:22-3.

Rai AJ, Udar N, Saad R, Fleisher M. A multiplex assay for detecting genetic variations in CYP2C9, VKORC1, and GGCX involved in warfarin metabolism. Clin Chem 2009; 55:823-6.

Raimundo S, Fischer J, Eichelbaum M, Griese EU, Schwab M, Zanger UM. Elucidation of the genetic basis of the common ‘intermediate metabolizer’ phenotype for drug oxidation by CYP2D6. Pharmacogenetics 2000; 10:577-81.

Raimundo S, Toscano C, Klein K et al. A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects. Clin Pharmacol Ther 2004; 76:128-38.

Raina AK, Hochman A, Zhu X et al. Abortive apoptosis in Alzheimer disease. Acta Neuropathol 2001; 101:305-10.

Rais N, Chawla YK, Kohli KK. CYP3A phenotypes and genotypes in North Indians. Eur J Clin Pharmacol 2006; 62:417-22.

Raizer J. Issues in developing drugs for primary brain tumors: barriers and toxicities. Toxicol Pathol 2011; 39:152-7.

Rajamannan NM. The role of Lrp5/6 in cardiac valve disease: Experimental hypercholesterolemia in the ApoE(-/-) /Lrp5(-/-) mice. J Cell Biochem 2011; 112:2987-91.

Rajan S, Ramu P, Umamaheswaran G, Adithan C. Association of aldosterone synthase (CYP11B2 C-344T) gene polymorphism & susceptibility to essential hypertension in a south Indian Tamil population. Indian J Med Res 2010; 132:379-85.

Rajaraman G, Yang G, Chen J, Chang TK. Modulation of CYP1B1 and CYP1A1 gene expression and activation of aryl hydrocarbon receptor by Ginkgo biloba extract in MCF-10A human mammary epithelial cells. Can J Physiol Pharmacol 2009; 87:674-83.

Rajaraman P, Hutchinson A, Wichner S et al. DNA repair gene polymorphisms and risk of adult meningioma, glioma, and acoustic neuroma. Neuro Oncol 2010; 12:37-48.

Rajender S, Rajani V, Gupta NJ, Chakravarty B, Singh L, Thangaraj K. No association of androgen receptor GGN repeat length polymorphism with infertility in Indian men. J Androl 2006; 27:785-9.

Rajender S, Singh L, Thangaraj K. Phenotypic heterogeneity of mutations in androgen receptor gene. Asian J Androl 2007; 9:147-79.

Rajendran P, Jaggi M, Singh MK, Mukherjee R, Burman AC. Pharmacological evaluation of C-3 modified Betulinic acid derivatives with potent anticancer activity. Invest New Drugs 2008; 26:25-34.

Rajić V, Aplenc R, Debeljak M et al. Influence of the polymorphism in candidate genes on late cardiac damage in patients treated due to acute leukemia in childhood. Leuk Lymphoma 2009; 50:1693-8.

Rajnai Z, Méhn D, Beéry E et al. ATP-binding cassette B1 transports seliciclib (R-roscovitine), a cyclin-dependent kinase inhibitor. Drug Metab Dispos 2010; 38:2000-6.

Rajnarayana K, Reddy MS, Vidyasagar J, Krishna DR. Study on the influence of silymarin pretreatment on metabolism and disposition of metronidazole. Arzneimittelforschung 2004; 54:109-13.

Rajpert-De Meyts E, Leffers H, Petersen JH et al. CAG repeat length in androgen-receptor gene and reproductive variables in fertile and infertile men. Lancet 2002; 359:44-6.

Raju R, Piggott AM, Huang XC, Capon RJ. Nocardioazines: A novel bridged diketopiperazine scaffold from a marine-derived bacterium inhibits P-glycoprotein. Org Lett 2011; 13:2770-3.

Rakhit A, Pantze MP, Fettner S et al. The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition. Eur J Clin Pharmacol 2008; 64:31-41.

Rakonjac M, Fischer L, Provost P et al. Coactosin-like protein supports 5-lipoxygenase enzyme activity and up-regulates leukotriene A(4) production. Proc Nat Acad Sci USA 2006; 103:13150-5.

Ramachandran S, Hoban PR, Ichii-Jones F et al. Glutathione S-transferase GSTP1 and cyclin D1 genotypes: association with numbers of basal cell carcinomas in a patient subgroup at high-risk of multiple tumours. Pharmacogenetics 2000; 10:545-56.

Ramacher M, Umansky V, Efferth T. Effect of artesunate on immune cells in ret-transgenic mouse melanoma model. Anticancer Drugs 2009; 20:910-7.

Ramadoss P, Marcus C, Perdew GH. Role of the aryl hydrocarbon receptor in drug metabolism. Expert Opin Drug Metab Toxicol 2005; 1:9-21.

Ramaekers JG, Conen S, de Kam PJ et al. Residual effects of esmirtazapine on actual driving performance: overall findings and an exploratory analysis into the role of CYP2D6 phenotype. Psychopharmacology 2011; 215:321-32.

Ramagopalan SV, Ebers GC. Multiple sclerosis: major histocompatibility complexity and antigen presentation. Genome Med 2009; 1:105.

Ramagopalan SV, Knight JC, Ebers GC. Multiple sclerosis and the major histocompatibility complex. Curr Opin Neurol 2009; 22:219-25.

Ramamoorthy Y, Yu AM, Suh N, Haining RL, Tyndale RF, Sellers EM. Reduced (+/-)-3,4-methylenedioxymethamphetamine (“Ecstasy”) metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro. Biochem Pharmacol 2002; 63:2111-9.

Raman KG, Gandley RE, Rohland J, Zenati MS, Tzeng E. Early hypercholesterolemia contributes to vasomotor dysfunction and injury associated atherogenesis that can be inhibited by nitric oxide. J Vasc Surg 2011; 53:754-63.

Ramanathan R, McKenzie DL, Tugnait M, Siebenaler K. Application of semi-automated metabolite identification software in the drug discovery process for rapid identification of metabolites and the cytochrome P450 enzymes responsible for their formation. J Pharm Biomed Anal 2002; 28:945-51.

Ramasamy K, Narayan SK, Shewade DG, Chandrasekaran A. Influence of CYP2C9 genetic polymorphism and undernourishment on plasma-free phenytoin concentrations in epileptic patients. Ther Drug Monit 2010; 32:762-6.

Ramasubbu R. Cerebrovascular effects of selective serotonin reuptake inhibitors: a systematic review. J Clin Psychiatry 2004; 65:1642-53.

Ramey-Hartung B, El-Mallakh RS, Reynolds KK. Pharmacogenetic testing in schizophrenia and posttraumatic stress disorder. Clin Lab Med 2008; 28:627-43.

Ramires R, Caiaffa MF, Tursi A, Haeggström JZ, Macchia L. Novel inhibitory effect on 5-lipoxygenase activity by the anti-asthma drug montelukast. Biochem Biophys Res Commun 2004; 324:815-21.

Ramirez CJ, Minch JD, Gay JM et al. Molecular genetic basis for fluoroquinolone-induced retinal degeneration in cats. Pharmacogenet Genomics 2011; 21:66-75.

Ramírez J, Innocenti F, Schuetz EG et al. CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes. Drug Metab Dispos 2004; 32:930-6.

Ramírez M, Prieto I, Alba F, Vives F, Banegas I, de Gasparo M. Role of central and peripheral aminopeptidase activities in the control of blood pressure: a working hypothesis. Heart Fail Rev 2008; 13:339-53.

Ramírez O, Tomàs A, Barragan C, Noguera JL, Amills M, Varona L. Pig melatonin receptor 1a (MTNR1A) genotype is associated with seasonal variation of sow litter size. Anim Reprod Sci 2009; 115:317-22.

Ramírez-Salazar M, Romero-Gutiérrez G, Zaina S, Malacara JM, Kornhauser C, Pérez-Luque E. Relationship of aldosterone synthase gene (C-344T) and mineralocorticoid receptor (S810L) polymorphisms with gestational hypertension. J Hum Hypertens 2011; 25:320-6.

Ramnarain DB, Park S, Lee DY et al. Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells. Cancer Res 2006; 66:867-74.

Ramón y Cajal T, Altés A, Paré L et al. Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment. Breast Cancer Res Treat 2010; 119:33-8

Ramos Cirilo PD, Rosa FE, Moreira Ferraz MF, Rainho CA, Pontes A, Regina Rogatto S. Genetic polymorphisms associated with steroids metabolism and insulin action in polycystic ovary syndrome. Gynecol Endocrinol 2011. doi:10. 3109/09513590. 2011. 593661.

Ramos EM, Lin MT, Larson EB et al. Tumor necrosis factor alpha and interleukin 10 promoter region polymorphisms and risk of late-onset Alzheimer disease. Arch Neurol 2006; 63:1165-9.

Ramos-Lopez E, Brück P, Jansen T, Herwig J, Badenhoop K. CYP2R1 (vitamin D 25-hydroxylase) gene is associated with susceptibility to type 1 diabetes and vitamin D levels in Germans. Diabetes Metab Res Rev 2007; 23:631-6.

Ramos-Lopez E, Brück P, Jansen T, Pfeilschifter JM, Radeke HH, Badenhoop K. CYP2R1-, CYP27B1- and CYP24-mRNA expression in German type 1 diabetes patients. J Steroid Biochem Mol Biol 2007; 103:807-10.

Ramoz N, Boni C, Downing AM et al. A haplotype of the norepinephrine transporter (Net) Gene Slc6a2 is associated with clinical response to atomoxetine in attention-deficit hyperactivity disorder (ADHD). Neuropsychopharmacology 2009; 34:2135-42.

Ramsjö M, Aklillu E, Bohman L, Ingelman-Sundberg M, Roh HK, Bertilsson L. CYP2C19 activity comparison between Swedes and Koreans: effect of genotype, sex, oral contraceptive use, and smoking. Eur J Clin Pharmacol 2010; 66:871-7.

Ramström C, Chapman H, Viitanen T et al. Regulation of HERG (KCNH2) potassium channel surface expression by diacylglycerol. Cell Mol Life Sci 2010; 67:157-69.

Ramus SJ, Harrington PA, Pye C et al. Contribution of BRCA1 and BRCA2 mutations to inherited ovarian cancer. Hum Mutat 2007; 28:1207-15.

Rana BK, Insel PA, Payne SH et al. Population-based sample reveals gene-gender interactions in blood pressure in White Americans. Hypertension 2007; 49:96-106.

Rana R, Chen Y, Ferguson SS, Kissling GE, Surapureddi S, Goldstein JA. Hepatocyte nuclear factor 4{alpha} regulates rifampicin-mediated induction of CYP2C genes in primary cultures of human hepatocytes. Drug Metab Dispos 2010; 38:591-9.

Ranade K, Jorgenson E, Sheu WHH et al. A polymorphism in the beta-1 adrenergic receptor is associated with resting heart rate. Am J Hum Genet 2002; 70:935-42.

Ranade K, Kirchgessner TG, Iakoubova OA et al. Evaluation of the paraoxonases as candidate genes for stroke: Gln192Arg polymorphism in the paraoxonase 1 gene is associated with increased risk of stroke. Stroke 2005; 36:2346-50.

Randolph AG, Lange C, Silverman EK et al. The IL12B gene is associated with asthma. Am J Hum Genet 2004; 75:709-15.

Ranen NG, Stine OC, Abbott MH et al. Anticipation and instability of IT-15 (CAG)n repeats in parent-offspring pairs with Huntigton disease. Am J Hum Genet 1995; 57:593-602.

Ranganathan P, Culverhouse R, Marsh S et al. Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis. J Rheumatol 2008; 35:572-9.

Rao AS, Camilleri M. Review article: metoclopramide and tardive dyskinesia. Aliment Pharmacol Ther 2010; 31:11-9.

Rao AV, Valk PJ, Metzeler KH et al. Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia. J Clin Oncol 2009; 27:5580-6.

Rao CV, Yang YM, Swamy MV et al. Colonic tumorigenesis in BubR1+/-ApcMin/+ compound mutant mice is linked to premature separation of sister chromatids and enhanced genomic instability. Proc Natl Acad Sci USA 2005; 102:4365-70.

Rao DN, Anuradha C, Vishnupriya S et al. Association of an MDR1 gene (C3435T) polymorphism with acute leukemia in India. Asian Pac J Cancer Prev 2010; 11:1063-6.

Rao ML, Hiemke C, Grasmäder K, Baumann P; TDM Arbeitsgruppe Der AGNP. Olanzapine: pharmacology, pharmacokinetics and therapeutic drug monitoring. Fortschr Neurol Psychiatr 2001; 69:510-7.

Rao N. The clinical pharmacokinetics of escitalopram. Clin Pharmacokinet 2007; 46:281-90.

Rao VS, Cupples LA, van Duijn CM et al. Evidence for major gene inheritance of Alzheimer’s disease in families of patients with and without apolipoprotein E epsilon-4. Am J Hum Genet 1996; 59:664-75.

Rao X, di Leva G, Li M et al. MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways. Oncogene 2011; 30:1082-97.

Rao Y, Hoffmann E, Zia M et al. Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking. Mol Pharmacol 2000; 58:747-55.

Rapaka RS, Coates PM. Dietary supplements and related products: a brief summary. Life Sci 2006; 78:2026-32.

Rapoport SI. Coupled reductions in brain oxidative phosphorylation and synaptic function can be quantified and staged in the course of Alzheimer disease. Neurotox Res 2003; 5:385-98.

Rasheeda MK, Sridevi P, Senthilkumaran B. Cytochrome P450 aromatases: Impact on gonadal development, recrudescence and effect of hCG in the catfish, Clarias gariepinus. Gen Comp Endocrinol 2010; 167:234-45.

Rashtchizadeh N, Aghaeishahsavari M, Argani H, Noroozianavval M, Veisi P, Ghorbanihaghjo A. Enalapril and losartan affect lipid peroxidation in renal transplant recipients with renin-angiotensin system polymorphisms. Clin Biochem 2007; 40:194-200.

Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000; 54:2261-8.

Rasmussen BB, Brix TH, Kyvik KO, Brosen K. The interindividual differences in the 3-demthylation (sic) of caffeine alias CYP1A2 is determined by both genetic and environmental factors. Pharmacogenetics 2002; 12:473-8.

Rasmussen BB, Brøsen K. Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? Ther Drug Monit 2000; 22:143-54.

Rasmussen BB, Nielsen TL, Brøsen K. Fluvoxamine inhibits the CYP2C19-catalysed metabolism of proguanil in vitro. Eur J Clin Pharmacol 1998; 54:735-40.

Rasmussen BB, Nielsen TL, Brøsen K. Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro. Pharmacol Toxicol 1998; 83:240-5.

Rasmussen E, Eriksson B, Oberg K, Bondesson U, Rane A. Selective effects of somatostatin analogs on human drug-metabolizing enzymes. Clin Pharmacol Ther 1998; 64:150-9.

Rasmussen M, Zamaratskaia G, Ekstrand B. Gender-related differences in cytochrome P450 in porcine liver – implication for activity, expression and inhibition by testicular steroids. Reprod Domest Anim 2011; 46:616-23.

Rasmussen MK, Zamaratskaia G, Ekstrand B. In vitro cytochrome P450 2E1 and 2A activities in the presence of testicular steroids. Reprod Domest Anim 2011; 46:149-54.

Rasmussen MK, Zamaratskaia G, Ekstrand B. In vivo effect of dried chicory root (Cichorium intybus L. ) on xenobiotica metabolising cytochrome P450 enzymes in porcine liver. Toxicol Lett 2011; 200:88-91.

Rasmussen SGF, Choi HJ, Rosenbaum D et al. Crystal structure of the human beta-2 adrenergic G-protein-coupled receptor. Nature 2007; 450:383-7.

Rasmussen-Torvik LJ, Pankow JS, Jacobs DR Jr, Steinberger J, Moran A, Sinaiko AR. The association of SNPs in ADIPOQ, ADIPOR1, and ADIPOR2 with insulin sensitivity in a cohort of adolescents and their parents. Hum Genet 2009; 125:21-8.

Rassas AA, Mrabet Khiari H, Hadj Fredj S et al. High APOE epsilon 4 allele frequencies associated with Alzheimer disease in a Tunisian population. Neurol Sci 2011. doi:10. 1007/s10072-011-0663-8.

Rastelli AL, Taylor ME, Gao F et al. Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial. Breast Cancer Res Treat 2011; 129:107-16.

Rastelli F, Crispino S. Factors predictive of response to hormone therapy in breast cancer. Tumori 2008; 94:370-83.

Rathkopf D, Carducci MA, Morris MJ et al. Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer. J Clin Oncol 2008; 26:2959-65.

Rathnayake D, Sinclair R. Innovative use of spironolactone as an antiandrogen in the treatment of female pattern hair loss. Dermatol Clin 2010; 28:611-8.

Rathore SS, Agarwal SK, Pande S, Mittal T, Mittal B. Frequencies of VKORC1 -1639 G>A, CYP2C9*2 and CYP2C9*3 genetic variants in the Northern Indian population. Biosci Trends 2010; 4:333-7.

Rathouska J, Vecerova L, Strasky Z et al. Endoglin as a possible marker of atorvastatin treatment benefit in atherosclerosis. Pharmacol Res 2011; 64:53-9.

Rathz DA, Brown KM, Kramer LA, Liggett SB. Amino acid 49 polymorphisms of the human beta1-adrenergic receptor affect agonist-promoted trafficking. J Cardiovasc Pharmacol 2002; 39:155-60.

Ratovitski T, Chighladze E, Waldron E, Hirschhorn RR, Ross CA. Cysteine proteases bleomycin hydrolase (BLMH) and cathepsin Z mediate N-terminal proteolysis and toxicity of mutant huntingtin. J Biol Chem 2011; 286:12578-89.

Rätz Bravo AE, Tchambaz L, Krähenbühl-Melcher A, Hess L, Schlienger RG, Krähenbühl S. Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy. Drug Saf 2005; 28:263-75.

Rau T, Diepenbruck S, Diepenbruck I, Eschenhagen T. The 2988G>A polymorphism affects splicing of a CYP2D6 minigene. Clin Pharmacol Ther 2006; 80:555-8.

Rau T, Erney B, Göres R, Eschenhagen T, Beck J, Langer T. High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations. Clin Pharmacol Ther 2006; 80:468-76.

Rau T, Heide R, Bergmann K et al. Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment. Pharmacogenetics 2002; 12:465-72.

Rau T, Wuttke H, Michels LM et al. Impact of the CYP2D6 genotype on the clinical effects of metoprolol: a prospective longitudinal study. Clin Pharmacol Ther 2009; 85:269-72.

Raucy J, Warfe L, Yueh MF, Allen SW. A cell-based reporter gene assay for determining induction of CYP3A4 in a high-volume system. J Pharmacol Exp Ther 2002; 303:412-23.

Raucy JL. Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products. Drug Metab Dispos 2003; 31:533-9.

Raucy JL, Mueller L, Duan K, Allen SW, Strom S, Lasker JM. Expression and induction of CYP2C P450 enzymes in primary cultures of human hepatocytes. J Pharmacol Exp Ther 2002; 302:475-82.

Rauch U, Saxena A, Lorkowski S et al. Laminin isoforms in atherosclerotic arteries from mice and man. Histol Histopathol 2011; 26:711-24.

Rauly-Lestienne I, Boutet-Robinet E, Ailhaud MC, Newman-Tancredi A, Cussac D. Differential profile of typical, atypical and third generation antipsychotics at human 5-HT7a receptors coupled to adenylyl cyclase: detection of agonist and inverse agonist properties. Naunyn Schmiedebergs Arch Pharmacol 2007; 376:93-105.

Raunio H, Hakkola J, Hukkanen J et al. Expression of xenobiotic-metabolizing CYPs in human pulmonary tissue. Exp Toxicol Pathol 1999; 51:412-7.

Raunio H, Hakkola J, Pelkonen O. Regulation of CYP3A genes in the human respiratory tract. Chem Biol Interact 2005; 151:53-62.

Rauschenbach R, Gieschen H, Husemann M, Salomon B, Hildebrand M. Stable expression of human cytochrome P450 3A4 in V79 cells and its application for metabolic profiling of ergot derivatives. Eur J Pharmacol 1995; 293:183-90.

Rausch-Fan X, Leutmezer F, Willheim M et al. Regulation of cytokine production in human peripheral blood mononuclear cells and allergen-specific th cell clones by 1alpha,25-dihydroxyvitamin D3. Int Arch Allergy Immunol 2002; 128:33-41.

Raux G, Gantier R, Thomas-Anterion C et al. Dementia with prominent frontotemporal features associated with L113P presenilin 1 mutation. Neurology 2000; 55:1577-8.

Ravikumar B, Duden R, Rubinsztein DC. Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autopathy. Hum Molec Genet 2002; 11:1107-17.

Ravikumar B, Vacher C, Berger Z et al. Inhibition of mTOR induces autopathy and reduces toxicity of poplyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet 2004; 36:585-96.

Ravindranath V, Kommaddi RP, Pai HV. Unique cytochromes P450 in human brain: implication in disease pathogenesis. J Neural Transm Suppl 2006; 167-71.

Ravindranathan A, Coon H, DeLisi L et al. Linkage analysis between schizophrenia and a microsatellite polymorphism for the D5 dopamine receptor gene. Psychiatr Genet 1994; 4:77-80.

Ravn K, Wibrand F, Hansen FJ, Horn N, Rosenberg T, Schwartz M. An mtDNA mutation, 14453G→A, in the NADH dehydrogenase subunit 6 associated with severe MELAS syndrome. Eur J Hum Genet 2001; 9:805-9.

Ravn LS, Benn M, Nordestgaard BG et al. Angiotensinogen and ACE gene polymorphisms and risk of atrial fibrillation in the general population. Pharmacogenet Genomics 2008; 18:525-33.

Rawden HC, Kokwaro GO, Ward SA, Edwards G. Relative contribution of cytochromes P-450 and flavin-containing monoxygenases to the metabolism of albendazole by human liver microsomes. Br J Clin Pharmacol 2000; 49:313-22.

Ray KK, Francis S, Crossman DC. A potential pharmacogenomic strategy for anticoagulant treatment in non-ST elevation acute coronary syndromes: the role of interleukin-1 receptor antagonist genotype. J Thromb Haemost 2005; 3:287-91.

Ray LA, Hutchison KE. A polymorphism of the mu-opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans. Alcohol Clin Exp Res 2004; 28:1789-95.

Ray WA, Meredith S, Thapa PB, Hall K, Murray KT. Cyclic antidepressants and the risk of sudden cardiac death. Clin Pharmacol Ther 2004; 75:234-41.

Rayasam GV, Tulasi VK, Sodhi R, Davis JA, Ray A. Glycogen synthase kinase 3: more than a namesake. Br J Pharmacol 2009; 156:885-98.

Raychaudhuri S, Remmers EF, Lee AT et al. Common variants at CD40 and other loci confer risk of rheumatoid arthritis. Nat Genet 2008; 40:1216-23.

Raynaud M, Moizard MP, Dessay B et al. Systematic analysis of X-inactivation in 19XLMR families: extremely skewed profiles in carriers in three families. Eur J Hum Genet 2000; 8:253-8.

Rayner KJ, Suárez Y, Dávalos A et al. MiR-33 contributes to the regulation of cholesterol homeostasis. Science 2010; 328:1570-3.

Razavi P, Lee E, Bernstein L, van den Berg D, Horn-Ross PL, Ursin G. Variations in sex hormone metabolism genes, postmenopausal hormone therapy and risk of endometrial cancer. Int J Cancer 2011. doi:10. 1002/ijc. 26163.

Razzaque MA, Nishizawa T, Komoike Y et al. Germline gain-of-function mutations in RAF1 cause Noonan syndrome. Nat Genet 2007; 39:1013-7.

Read AP. Huntington’s disease: testing the test. Nat Genet 1993; 4:329-30.

Real R, Egido E, Pérez M et al. Involvement of breast cancer resistance protein (BCRP/ABCG2) in the secretion of danofloxacin into milk: interaction with ivermectin. J Vet Pharmacol Ther 2011; 34:313-21.

Reardon DA, Desjardins A, Vredenburgh JJ et al. Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma. Neuro Oncol 2008; 10:330-40.

Reardon DA, Quinn JA, Rich JN et al. Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma. Neuro Oncol 2004; 6:134-44.

Reardon DA, Quinn JA, Rich JN et al. Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma. Cancer 2005; 104:1478-86.

Reaux A, Iturrioz X, Vazeux G et al. Aminopeptidase A, which generates one of the main effector peptides of the brain renin-angiotensin system, angiotensin III, has a key role in central control of arterial blood pressure. Biochem Soc Trans 2000; 28:435-40.

Rebaï M, Kallel I, Hamza F et al. Association of EGFR and HER2 polymorphisms with risk and clinical features of thyroid cancer. Genet Test Mol Biomarkers 2009; 13:779-84.

Rebbeck TR, Jaffe JM, Walker AH, Wein AJ, Malkowicz SB. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 1998; 90:1225-9.

Rebbeck TR, Rennert H, Walker AH et al. Joint effects of inflammation and androgen metabolism on prostate cancer severity. Int J Cancer 2008; 123:1385-9.

Rebbeck TR, Su HI, Sammel MD et al. Effect of hormone metabolism genotypes on steroid hormone levels and menopausal symptoms in a prospective population-based cohort of women experiencing the menopausal transition. Menopause 2010; 17:1026-34.

Rebbeck TR, Troxel AB, Norman S et al. Pharmacogenetic modulation of combined hormone replacement therapy by progesterone-metabolism genotypes in postmenopausal breast cancer risk. Am J Epidemiol 2007; 166:1392-9.

Rebbeck TR, Troxel AB, Walker AH et al. Pairwise combinations of estrogen metabolism genotypes in postmenopausal breast cancer etiology. Cancer Epidemiol Biomarkers Prev 2007; 16:444-50.

Rebbeck TR, Troxel AB, Wang Y et al. Estrogen sulfation genes, hormone replacement therapy, and endometrial cancer risk. J Natl Cancer Inst 2006; 98:1311-20.

Rebecchi IM, Rodrigues AC, Arazi SS et al. ABCB1 and ABCC1 expression in peripheral mononuclear cells is influenced by gene polymorphisms and atorvastatin treatment. Biochem Pharmacol 2009; 77:66-75.

Rebello S, Leon S, Hariry S, Dahlke M, Jarugula V. Effect of verapamil on the pharmacokinetics of aliskiren in healthy participants. J Clin Pharmacol 2011; 51:218-28.

Rebholz SL, Burke KT, Yang Q, Tso P, Woollett LA. Dietary fat impacts fetal growth and metabolism: uptake of chylomicron remnant core lipids by the placenta. Am J Physiol Endocrinol Metab 2011; 301:416-25.

Rebsamen MC, Desmeules J, Daali Y et al. The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction. Pharmacogenomics J 2009; 9:34-41.

Rector A, Vermeire S, Thoelen I et al. Analysis of the CC chemokine receptor 5 (CCR5) delta-32 polymorphism in inflammatory bowel disease. Hum Genet 2001; 108:190-3.

Redaelli S, Piazza R, Rostagno R et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol 2009; 27:469-71.

Reding KW, Li CI, Weiss NS et al. Genetic variation in the progesterone receptor and metabolism pathways and hormone therapy in relation to breast cancer risk. Am J Epidemiol 2009; 170:1241-9.

Redlich G, Zanger UM, Riedmaier S et al. Distinction between human cytochrome P450 (CYP) isoforms and identification of new phosphorylation sites by mass spectrometry. J Proteome Res 2008; 7:4678-88.

Redon J, Luque-Otero M, Martell N, Chaves FJ; POLPRI Investigators. Renin-angiotensin system gene polymorphisms: relationship with blood pressure and microalbuminuria in telmisartan-treated hypertensive patients. Pharmacogenomics J 2005; 5:14-20.

Reed JR, Cawley GF, Backes WL. Inhibition of cytochrome P450 1A2-mediated metabolism and production of reactive oxygen species by heme oxygenase-1 in rat liver microsomes. Drug Metab Lett 2011; 5:6-16.

Reed K, Hembruff SL, Sprowl JA, Parissenti AM. The temporal relationship between ABCB1 promoter hypomethylation, ABCB1 expression and acquisition of drug resistance. Pharmacogenomics J 2010; 10:489-504.

Reed LA, Grabowsky TJ, Schmidt ML et al. Autosomal dominant dementia with widespread neurofibrillary tangles. Ann Neurol 1997; 42:564-72.

Reed M, Wall GC, Shah NP, Heun JM, Hicklin GA. Verapamil toxicity resulting from a probable interaction with telithromycin. Ann Pharmacother 2005; 39:357-60.

Reena MB, Gowda LR, Lokesh BR. Enhanced hypocholesterolemic effects of interesterified oils are mediated by upregulating LDL receptor and cholesterol 7-α- hydroxylase gene expression in rats. J Nutr 2011; 141:24-30.

Reese MJ, Wurm RM, Muir KT, Generaux GT, St John-Williams L, McConn DJ. An in vitro mechanistic study to elucidate the desipramine/bupropion clinical drug-drug interaction. Drug Metab Dispos 2008; 36:1198-201.

Regan CF, Guo Z, Chen Y et al. Zwitterionic uracil derivatives as potent GnRH receptor antagonists with improved pharmaceutical properties. Bioorg Med Chem Lett 2008; 18:4503-7.

Reger TS, Zunic J, Stock N et al. Heterocycle-substituted proline dipeptides as potent VLA-4 antagonists. Bioorg Med Chem Lett 2010; 20:1173-6.

Regev M, Barzilai SE, Figer A, Zidan J, Fidder HH, Friedman E. The I1307K APC mutation in a high-risk clinic setting: a follow-up study. Clin Genet 2005; 67:352-5.

Regev-Shoshani G, Shoseyov O, Kerem Z. Influence of lipophilicity on the interactions of hydroxy stilbenes with cytochrome P450 3A4. Biochem Biophys Res Commun 2004; 323:668-73.

Regitz-Zagrosek V, Hocher B, Bettmann M et al. Alpha2C-adrenoceptor polymorphism is associated with improved event-free survival in patients with dilated cardiomyopathy. Eur Heart J 2006; 27:454-9.

Rehmel JL, Eckstein JA, Farid NA et al. Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450. Drug Metab Dispos 2006; 34:600-7.

Rehnström K, Ylisaukko-oja T, Nummela I et al. Allelic variants in HTR3C show association with autism. Am J Med Genet B Neuropsychiatr Genet 2009; 150:741-6.

Reich D, Patterson N, Ramesh V et al. Admixture mapping of an allele affecting interleukin 6 soluble receptor and interleukin 6 levels. Am J Hum Genet 2007; 80:716-26.

Reich T, Edenberg HJ, Goate A et al. Genome-wide search for genes affecting the risk for alcohol dependence. Am J Med Genet 1998; 81:207-15.

Reiche EM, Bonametti AM, Voltarelli JC, Morimoto HK, Watanabe MA. Genetic polymorphisms in the chemokine and chemokine receptors: impact on clinical course and therapy of the human immunodeficiency virus type 1 infection (HIV-1). Curr Med Chem 2007; 14:1325-34.

Reichel C, Block W, Skodra T et al. Relationship between cytochrome P-450 induction by rifampicin, hepatic volume and portal blood flow in man. Eur J Gastroenterol Hepatol 1997; 9:975-9.

Reichel C, Skodra T, Nacke A, Spengler U, Sauerbruch T. The lignocaine metabolite (MEGX) liver function test and P-450 induction in humans. Br J Clin Pharmacol 1998; 46:535-9.

Reichel V, Burghard S, John I, Huber O. P-glycoprotein and breast cancer resistance protein expression and function at the blood-brain barrier and blood-cerebrospinal fluid barrier (choroid plexus) in streptozotocin-induced diabetes in rats. Brain Res 2011; 1370:238-45.

Reichl FX, Seiss M, Buters J, Behrendt H, Hickel R, Durner J. Expression of CYP450-2E1 and formation of 2,3-epoxymethacrylic acid (2,3-EMA) in human oral cells exposed to dental materials. Dent Mater 2010; 26:1151-6.

Reichmuth D, Lockey RF. Present and potential therapy for allergic rhinitis: a review. BioDrugs 2000; 14:371-87.

Reichrath J, Rech M, Moeini M, Meese E, Tilgen W, Seifert M. In vitro comparison of the vitamin D endocrine system in 1,25(OH)2D3-responsive and -resistant melanoma cells. Cancer Biol Ther 2007; 6:48-55.

Reid G, Wielinga P, Zelcer N et al. The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci USA 2003; 100:9244-9.

Reid JM, Kuffel MJ, Ruben SL et al. Rat and human liver cytochrome P-450 isoform metabolism of ecteinascidin 743 does not predict gender-dependent toxicity in humans. Clin Cancer Res 2002; 8:2952-62.

Reid JM, Walker DL, Miller JK et al. The metabolism of pyrazoloacridine (NSC 366140) by cytochromes p450 and flavin monooxygenase in human liver microsomes. Clin Cancer Res 2004; 10:1471-80.

Reif A, Grünblatt E, Herterich S et al. Association of a functional NOS1 promoter repeat with Alzheimer’s disease in the VITA cohort. J Alzheimers Dis 2011; 23:327-33.

Reik W. Genomic impriminting: a possible mechanism for the parental origin effect in Huntington’s chorea. J Med Genet 1988; 25:805-8.

Reik W. Genomic imprinting and genetic disorders in man. Trends Genet 1989; 5:331-6.

Reik W, Collick A, Norris ML, Barton SC, Surani MA. Genomic impriting determines methylation of parental alleles in transgenic mice. Nature 1987; 328:248-51.

Reilly PE, Mason SR, Read MA. Human, rat and crocodile liver microsomal monooxygenase activities measured using diazepam and nifedipine: effects of CYP3A inhibitors and relationship to immunochemically detected CYP3A apoprotein. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 1999; 122:197-204.

Reiman EM, Caselli RJ, Chen K, Alexander GE, Bandy D, Frost J. Declining brain activity in cognitively normal apolipoprotein E epsilon-4 heterozygotes: a foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer’s disease. Proc Nat Acad Sci USA 2001; 98:3334-9.

Reiman EM, Caselli RJ, Yun LS et al. Preclinical evidence of Alzheimer’s disease in persons homozygous for the epsilon-4 allele for apolipoprotein E. New Engl J Med 1996; 334:752-8.

Reiman EM, Chen K, Alexander GE et al. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer’s dementia. Proc Natl Acad Sci USA 2004; 101:284-9.

Reimers A, Østby L, Stuen I, Sundby E. Expression of UDP-glucuronosyltransferase 1A4 in human placenta at term. Eur J Drug Metab Pharmacokinet 2011; 35:79-82.

Reinach B, de Sousa G, Dostert P, Ings R, Gugenheim J, Rahmani R. Comparative effects of rifabutin and rifampicin on cytochromes P450 and UDP-glucuronosyl-transferases expression in fresh and cryopreserved human hepatocytes. Chem Biol Interact 1999; 121:37-48.

Reiner A, Albin RL, Anderson KD et al. Differential loss stritatal projection in Huntigton disease. Proc Nat Acad Sci USA 1998; 85:5733-7.

Reiner AP, Carty CL, Carlson CS et al. Association between patterns of nucleotide variation across the three fibrinogen genes and plasma fibrinogen levels: the Coronary Artery Risk Development in Young Adults (CARDIA) study. J Thromb Haemost 2006; 4:1279-87.

Reines SA, Block GA, Morris JC et al. Rofecoxib: no effect on Alzheimer’s disease in a 1-year, randomized, blinded, controlled study. Neurology 2004; 62:66-71.

Reinicke KE, Kuffel MJ, Goetz MP, Ames MM. Synergistic interactions between aminoflavone, paclitaxel and camptothecin in human breast cancer cells. Cancer Chemother Pharmacol 2010; 66:575-83.

Reinold H, Ahmadi S, Depner UB et al. Spinal inflammatory hyperalgesia is mediated by prostaglandin E receptors of the EP2 subtype. J Clin Invest 2005; 115:673-9.

Reis KA, Onal B, Gonen S et al. Angiotensinogen and plasminogen activator inhibitor-1 gene polymorphism in relation to renovascular disease. Cardiovasc Intervent Radiol 2006; 29:59-63.

Reisberg B, Doody R, Stoffler A et al. Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med 2003; 348:1333-41.

Reiss AB, Anwar K, Merrill JT et al. Plasma from systemic lupus patients compromises cholesterol homeostasis: a potential mechanism linking autoimmunity to atherosclerotic cardiovascular disease. Rheumatol Int 2010; 30:591-8.

Reiss AB, Carsons SE, Anwar K et al. Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte/macrophages. Arthritis Rheum 2008; 58:3675-83.

Reitman ML, Chu X, Cai X et al. Rifampin’s acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug-drug interaction trial design. Clin Pharmacol Ther 2011; 89:234-42.

Reitsma PH, Bernardi F, Doig RG et al. Protein C deficiency: a database of mutations, 1995 update. On behalf of the Subcommittee on Plasma Coagulation Inhibitors of the Scientific and Standardization Committee of the ISTH. Thromb Haemost 1995; 73:876-89.

Reitsma PH, Poort SR, Allaart CF, Briët E, Bertina RM. The spectrum of genetic defects in a panel of 40 Dutch families with symptomatic protein C deficiency type I: heterogeneity and founder effects. Blood 1991; 78:890-4.

Reitz C, Tang MX, Schupf N, Manly JJ, Mayeux R, Luchsinger JA. Association of higher levels of high-density lipoprotein cholesterol in elderly individuals and lower risk of late-onset Alzheimer disease. Arch Neurol 2010; 67:1491-7.

Rejeb J, Omezzine A, Rebhi L et al. Associations between common polymorphisms of adenosine triphosphate-binding cassette transporter A1 and coronary artery disease in a Tunisian population. Arch Cardiovasc Dis 2010; 103:530-7.

Relling MV, Evans WE, Fonné-Pfister R, Meyer UA. Anticancer drugs as inhibitors of two polymorphic cytochrome P450 enzymes, debrisoquin and mephenytoin hydroxylase, in human liver microsomes. Cancer Res 1989; 49:68-71.

Relling MV, Hancock ML, Rivera GK et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 1999; 91:2001-8.

Relling MV, Nemec J, Schuetz EG, Schuetz JD, Gonzalez FJ, Korzekwa KR. O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4. Mol Pharmacol 1994; 45:352-8.

Remaley AT, Rust S, Rosier M et al. Human ATP-binding cassette transporter 1 (ABC1): genomic organization and identification of the genetic defect in the original Tangier disease kindred. Proc Nat Acad Sci USA 1999; 96:12685-90.

Remmel RP, Crews BC, Kozak KR, Kalgutkar AS, Marnett LJ. Studies on the metabolism of the novel, selective cyclooxygenase-2 inhibitor indomethacin phenethylamide in rat, mouse, and human liver microsomes: identification of active metabolites. Drug Metab Dispos 2004; 32:113-22.

Ren J, Pulakat L, Whaley-Connell A, Sowers JR. Mitochondrial biogenesis in the metabolic syndrome and cardiovascular disease. J Mol Med 2010; 88:993-1001.

Ren Q, Liang YJ, He H, Fu L, Gu Y. A facile synthesis and biological activity of novel tetrahydrobenzo[4’,5’]thieno[3’,2’:5,6]pyrido[4,3-d]pyrimidin-4(3H)-ones. Bioorg Med Chem Lett 2009; 19:6713-6.

Ren S, Hylemon P, Zhang ZP et al. Identification of a novel sulfonated oxysterol, 5-cholesten-3beta,25-diol 3-sulfonate, in hepatocyte nuclei and mitochondria. J Lipid Res 2006; 47:1081-90.

Ren S, Yang JS, Kalhorn TF, Slattery JT. Oxidation of cyclophosphamide to 4-hydroxycyclophosphamide and deschloroethylcyclophosphamide in human liver microsomes. Cancer Res 1997; 57:4229-35.

Ren S, Yu H, Zhang H et al. Polymorphisms of interferon-inducible genes OAS associated with interferon-α treatment response in chronic HBV infection. Antiviral Res 2011; 89:232-7.

Ren X, Mao X, Si L et al. Pharmaceutical excipients inhibit cytochrome P450 activity in cell free systems and after systemic administration. Eur J Pharm Biopharm 2008; 70:279-88.

Ren X, Xu C, Zhan C et al. Identification of NPPA variants associated with atrial fibrillation in a Chinese GeneID population. Clin Chim Acta 2010; 411:481-5.

Renbarger JL, McCammack KC, Rouse CE, Hall SD. Effect of race on vincristine-associated neurotoxicity in pediatric acute lymphoblastic leukemia patients. Pediatr Blood Cancer 2008; 50:769-71.

Rencurel F, Foretz M, Kaufmann MR et al. Stimulation of AMP-activated protein kinase is essential for the induction of drug metabolizing enzymes by phenobarbital in human and mouse liver. Mol Pharmacol 2006; 70:1925-34.

Renders L, Frisman M, Ufer M et al. CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. Clin Pharmacol Ther 2007; 81:228-34.

Rendic S, Nolteernsting E, Schänzer W. Metabolism of anabolic steroids by recombinant human cytochrome P450 enzymes. Gas chromatographic-mass spectrometric determination of metabolites. J Chromatogr B Biomed Sci Appl 1999; 735:73-83.

Renner W, Nauck M, Winkelmann BR et al. Association of angiotensinogen haplotypes with angiotensinogen levels but not with blood pressure or coronary artery disease: the Ludwigshafen Risk and Cardiovascular Health Study. J Mol Med 2005; 83:235-9.

Rentzsch B, Todiras M, Iliescu R et al. Transgenic angiotensin-converting enzyme 2 overexpression in vessels of SHRSP rats reduces blood pressure and improves endothelial function. Hypertension 2008; 52:967-73.

Renwick AB, Lewis DF, Fulford S et al. Metabolism of 2,5-bis(trifluoromethyl)-7-benzyloxy-4-trifluoromethylcoumarin by human hepatic CYP isoforms: evidence for selectivity towards CYP3A4. Xenobiotica 2001; 31:187-204.

Renwick AB, Mistry H, Ball SE, Walters DG, Kao J, Lake BG. Metabolism of Zaleplon by human hepatic microsomal cytochrome P450 isoforms. Xenobiotica 1998; 28:337-48.

Renwick AB, Surry D, Price RJ, Lake BG, Evans DC. Metabolism of 7-benzyloxy-4-trifluoromethyl-coumarin by human hepatic cytochrome P450 isoforms. Xenobiotica 2000; 30:955-69.

Renwick AB, Watts PS, Edwards RJ et al. Differential maintenance of cytochrome P450 enzymes in cultured precision-cut human liver slices. Drug Metab Dispos 2000; 28:1202-9.

Repa JJ, Turley SD, Lobaccaro JMA et al. Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science 2000; 289:1524-9.

Reppe S, Refvem H, Gautvik VT et al. Eight genes are highly associated with BMD variation in postmenopausal Caucasian women. Bone 2010; 46:604-12.

Ressiniotis T, Griffiths PG, Birch M, Keers S, Chinnery PF. The role of apolipoprotein E gene polymorphisms in primary open-angle glaucoma. Arch Ophthalmol 2004; 122:258-61.

Ressler KJ, Bradley B, Mercer KB et al. Polymorphisms in CRHR1 and the serotonin transporter loci: gene x gene x environment interactions on depressive symptoms. Am J Med Genet B Neuropsychiatr Genet 2010; 153:812-24.

Restrepo JG, García-Martín E, Martínez C, Agúndez JA. Polymorphic drug metabolism in anaesthesia. Curr Drug Metab 2009; 10:236-46.

Rétey JV, Adam M, Khatami R et al. A genetic variation in the adenosine A2A receptor gene (ADORA2A) contributes to individual sensitivity to caffeine effects on sleep. Clin Pharmacol Ther 2007; 81:692-8.

Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 1994; 4:39-42.

Revermann M, Mieth A, Popescu L et al. A pirinixic acid derivative (LP105) inhibits murine 5-lipoxygenase activity and attenuates vascular remodelling in a murine aortic aneurysm model. Br J Pharmacol 2011; 163:1721-32.

Rexrode KM, Ridker PM, Hegener HH, Buring JE, Manson JE, Zee RY. Polymorphisms and haplotypes of the estrogen receptor-beta gene (ESR2) and cardiovascular disease in men and women. Clin Chem 2007; 53:1749-56.

Rey E, Tréluyer JM, Pons G. Drug disposition in cystic fibrosis. Clin Pharmacokinet 1998; 35:313-29.

Rey JW, Noetel A, Hardt A et al. Pro12Ala polymorphism of the peroxisome proliferator-activated receptor γ2 in patients with fatty liver diseases. World J Gastroenterol 2010; 16:5830-7.

Reyes-Gibby CC, Shete S, Rakvåg T et al. Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene. Pain 2007; 130:25-30.

Reyes-Hernández OD, Lares-Asseff I, Sosa-Macias M, Vega L, Albores A, Elizondo G. A comparative study of CYP3A4 polymorphisms in Mexican Amerindian and Mestizo populations. Pharmacology 2008; 81:97-103.

Reyhanian N, Volkova K, Hallgren S et al. 17α-Ethinyl estradiol affects anxiety and shoaling behavior in adult male zebra fish (Danio rerio). Aquat Toxicol 2011; 105:41-8.

Reynolds GP, Hill MJ, Kirk SL. The 5-HT2C receptor and antipsychoticinduced weight gain – mechanisms and genetics. J Psychopharmacol 2006; 20(4 Suppl):15-8.

Reynolds GP, Kirk SL. Metabolic side effects of antipsychotic drug treatment-pharmacological mechanisms. Pharmacol Ther 2010; 125:169-79.

Reynolds GP, Yao Z, Zhang X, Sun J, Zhang Z. Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response. Eur Neuropsychopharmacol 2005; 15:143-51.

Rezaei N, Aghamohammadi A, Mahmoudi M et al. Association of IL-4 and IL-10 gene promoter polymorphisms with common variable immunodeficiency. Immunobiology 2010; 215:81-7.

Rezaei-Ghaleh N, Giller K, Becker S, Zweckstetter M. Effect of zinc binding on β-amyloid structure and dynamics: Implications for Aβ aggregation. Biophys J 2011; 101:1202-11.

Rezaï K, Lokiec F, Grandjean I et al. Impact of imatinib on the pharmacokinetics and in vivo efficacy of etoposide and/or ifosfamide. BMC Pharmacol 2007; 7:13.

Rheeders M, Bouwer M, Goosen TC. Drug-drug interaction after single oral doses of the furanocoumarin methoxsalen and cyclosporine. J Clin Pharmacol 2006; 46:768-75.

Rhodes B, Morris DL, Subrahmanyan L et al. Fine-mapping the genetic basis of CRP regulation in African Americans: a Bayesian approach. Hum Genet 2008; 123:633-42.

Rhodes DR, Ateeq B, Cao Q et al. AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist. Proc Natl Acad Sci USA 2009; 106:10284-9.

Rhodes SP, Otten JN, Hingorani GP, Hartley DP, Franklin RB. Simultaneous assessment of cytochrome P450 activity in cultured human hepatocytes for compound-mediated induction of CYP3A4, CYP2B6, and CYP1A2. J Pharmacol Toxicol Methods 2011; 63:223-6.

Rial D, Duarte FS, Xikota JC et al. Cellular prion protein modulates age-related behavioral and neurochemical alterations in mice. Neuroscience 2009; 164:896-907.

Riancho JA, García-Ibarbia C, Gravani A et al. Common variations in estrogen-related genes are associated with severe large-joint osteoarthritis: a multicenter genetic and functional study. Osteoarthritis Cartilage 2010; 18:927-33.

Riancho JA, Valero C, Naranjo A, Morales DJ, Sañudo C, Zarrabeitia MT. Identification of an aromatase haplotype that is associated with gene expression and postmenopausal osteoporosis. J Clin Endocrinol Metab 2007; 92:660-5.

Riazanskaia N, Lukiw WJ, Grigorenko A et al. Regulatory region variability in the human presenilin-2 (PSEN2) gene: potential contribution to the gene activity and risk for AD. Mol Psychiatry 2002; 7:891-8.

Ribaudo HJ, Liu H, Schwab M et al. Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study. J Infect Dis 2010; 202:717-22.

Ribeiro A, Pastier D, Kardassis D, Chambaz J, Cardot P. Cooperative binding of upstream stimulatory factor and hepatic nuclear factor 4 drives the transcription of the human apolipoprotein A-II gene. J Biol Chem 1999; 274:1216-25.

Ribeiro I, Marcão A, Amaral O, Sá Miranda MC, Vanier MT, Millat G. Niemann-Pick type C disease: NPC1 mutations associated with severe and mild cellular cholesterol trafficking alterations. Hum Genet 2001; 109:24-32.

Ribonnet L, Callebaut A, Nobels I et al. Modulation of CYP1A1 activity by a Ginkgo biloba extract in the human intestinal Caco-2 cells. Toxicol Lett 2011; 202:193-202.

Ribrag V, Koscielny S, Casasnovas O et al. Pharmacogenetic study in Hodgkin lymphomas reveals the impact of UGT1A1 polymorphisms on patient prognosis. Blood 2009; 113:3307-13.

Ricaurte B, Guirguis A, Taylor HC, Zabriskie D. Simvastatin-amiodarone interaction resulting in rhabdomyolysis, azotemia, and possible hepatotoxicity. Ann Pharmacother 2006; 40:753-7.

Ricci R, Sumara G, Sumara I et al. Requirement of JNK2 for scavenger receptor A-mediated foam cell formation in atherogenesis. Science 2004; 306:1558-61.

Riccio A, Sparago A, Verde G et al. Inherited and Sporadic Epimutations at the IGF2-H19 locus in Beckwith-Wiedemann syndrome and Wilms’ tumor. Endocr Dev 2009; 14:1-9.

Riccioni R, Dupuis ML, Bernabei M et al. The cancer stem cell selective inhibitor salinomycin is a p-glycoprotein inhibitor. Blood Cells Mol Dis 2010; 45:86-92.

Ricchiuti V, Lapointe N, Pojoga L et al. Dietary sodium intake regulates angiotensin II type 1, mineralocorticoid receptor and associated signaling proteins in heart. J Endocrinol 2011; 211:47-54.

Rickel EA, Siegel LA, Yoon BR et al. Identification of functional roles for both IL-17RB and IL-17RA in mediating IL-25-induced activities. J Immunol 2008; 181:4299-310.

Ricketts MH, Hamer RM, Manowitz P et al. Association of long variants of the dopamine D4 receptor exon 3 repeat polymorphism with Parkinson’s disease. Clin Genet 1998; 54:33-8.

Ricketts ML, Boekschoten MV, Kreeft AJ et al. The cholesterol-raising factor from coffee beans, cafestol, as an agonist ligand for the farnesoid and pregnane X receptors. Mol Endocrinol 2007; 21:1603-16.

Richard T, Pawlus AD, Iglésias ML et al. Neuroprotective properties of resveratrol and derivatives. Ann N Y Acad Sci 2011; 1215:103-8.

Richards DB, Walker GA, Mandagere A, Magee MH, Henderson LS. Effect of ketoconazole on the pharmacokinetic profile of ambrisentan. J Clin Pharmacol 2009; 49:719-24.

Richardson TH, Jung F, Griffin KJ et al. A universal approach to the expression of human and rabbit cytochrome P450s of the 2C subfamily in Escherichia coli. Arch Biochem Biophys 1995; 323:87-96.

Richeldi L, Sorrentino R, Saltini C. HLA-DPB1 glutamate 69: a genetic marker of beryllium disease. Science 1993; 262:242-4.

Richelson E. Pharmacokinetic drug interactions of new antidepressants: a review of the effects on the metabolism of other drugs. Mayo Clin Proc 1997; 72:835-47.

Richert L, Abadie C, Bonet A et al. Inter-laboratory evaluation of the response of primary human hepatocyte cultures to model CYP inducers – a European Centre for Validation of Alternative Methods (ECVAM) – funded pre-validation study. Toxicol In Vitro 2010; 24:335-45.

Richert L, Chevalley T, Manen D, Bonjour JP, Rizzoli R, Ferrari S. Bone mass in prepubertal boys is associated with a Gln223Arg amino acid substitution in the leptin receptor. J Clin Endocrinol Metab 2007; 92:4380-6.

Richert L, Tuschl G, Abadie C et al. Use of mRNA expression to detect the induction of drug metabolising enzymes in rat and human hepatocytes. Toxicol Appl Pharmacol 2009; 235:86-96.

Richfield EK, Herkenham M. Selective vulnerability in Huntigton’s disease: preferential loss of cannabinoid receptors in lateral globus pallidus. Ann Neurol 1994; 36:577-84.

Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch C. Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes. Vasc Health Risk Manag 2008; 4:753-68.

Richter-Schmidinger T, Alexopoulos P, Horn M et al. Influence of brain-derived neurotrophic-factor and apolipoprotein E genetic variants on hippocampal volume and memory performance in healthy young adults. J Neural Transm 2011; 118:249-57.

Rideg O, Háber A, Botz L et al. Pilot study for the characterization of pharmacogenetically relevant CYP2D6, CYP2C19 and ABCB1 gene polymorphisms in the Hungarian population. Cell Biochem Funct 2011; 29:562-8.

Ridker PM, Hennekens CH, Lindpaintner K et al. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332:912-7.

Ridker PM, Pare G, Parker A et al. Loci related to metabolic syndrome pathways including LEPR,HNF1A, IL6R, and GCKR associate with plasma C-reactive protein: the Women’s Genome Health Study. Am J Hum Genet 2008; 82:1185-92.

Ridley RM, Frith CD, Crown TJ, Connelly PM. Anticipation in Huntington’s disease is inherited through the male line but may orginate in the female. J Med Genet 1988; 25:589-95.

Ridley RM, Frith CD, Farrer LA, Conneally PM. Patterns of inheritance of the symptoms of Huntington’s disease suggestive of an effect of genomic imprinting. J Med Genet 1991; 28; 224-31.

Ridruechai C, Mahasirimongkol S, Phromjai J et al. Association analysis of susceptibility candidate region on chromosome 5q31 for tuberculosis. Genes Immun 2010; 11:416-22.

Ridtitid W, Ratsamemonthon K, Mahatthanatrakul W, Wongnawa M. Pharmacokinetic interaction between ketoconazole and praziquantel in healthy volunteers. J Clin Pharm Ther 2007; 32:585-93.

Ridtitid W, Wongnawa M, Mahatthanatrakul W, Chaipol P, Sunbhanich M. Effect of rifampin on plasma concentrations of mefloquine in healthy volunteers. J Pharm Pharmacol 2000; 52:1265-9.

Ridtitid W, Wongnawa M, Mahatthanatrakul W, Punyo J, Sunbhanich M. Rifampin markedly decreases plasma concentrations of praziquantel in healthy volunteers. Clin Pharmacol Ther 2002; 72:505-13.

Ridtitid W, Wongnawa M, Mahatthanatrakul W, Raungsri N, Sunbhanich M. Ketoconazole increases plasma concentrations of antimalarial mefloquine in healthy human volunteers. J Clin Pharm Ther 2005; 30:285-90.

Rieder MJ, Reiner AP, Gage BF et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. New Eng J Med 2005; 352:2285-93.

Rieder MJ, Reiner AP, Rettie AE. Gamma-glutamyl carboxylase (GGCX) tagSNPs have limited utility for predicting warfarin maintenance dose. J Thromb Haemost 2007; 5:2227-34.

Riedmaier S, Klein K, Hofmann U et al. UDP-glucuronosyltransferase (UGT) polymorphisms affect atorvastatin lactonization in vitro and in vivo. Clin Pharmacol Ther 2010; 87:65-73.

Riek R, Wider G, Billeter M, Hornemann S, Glockshuber R, Wüthrich K. Prion protein NMR structure and familial human spongiform encephalopathies. Proc Nat Acad Sci USA 1998; 95:11667-72.

Riemenschneider M, Klopp N, Xiang W et al. Prion protein codon 129 polymorphism and risk of Alzheimer disease. Neurology 2004; 63:364-6.

Riemsma R, Forbes CA, Kessels A et al. Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer. Breast Cancer Res Treat 2010; 123:9-24.

Rietchel M, Kraub H, Müller DJ et al. Apolipoprotein E epsilon 4 and clinical phenotype in schizophrenia. Lancet 1997; 350:1857-8.

Rieutord A, Stupans I, Shenfield GM, Gross AS. Gliclazide hydroxylation by rat liver microsomes. Xenobiotica 1995; 25:1345-54.

Riffel AK, Schuenemann E, Vyhlidal CA. Regulation of the CYP3A4 and CYP3A7 promoters by members of the nuclear factor I transcription factor family. Mol Pharmacol 2009; 76:1104-14.

Rigalli JP, Ruiz ML, Perdomo VG, Villanueva SS, Mottino AD, Catania VA. Pregnane X receptor mediates the induction of P-glycoprotein by spironolactone in HepG2 cells. Toxicology 2011; 285:18-24.

Riganti C, Voena C, Kopecka J et al. Liposome-encapsulated doxorubicin reverses drug-resistance by inhibiting P-glycoprotein in human cancer cells. Mol Pharm 2011; 8:683-700.

Rigat B, Hubert C, Corvol P, Soubrier F. PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidylcarboxypeptidase 1). Nucleic Acids Res 1992; 20:1433.

Rigaud AS, Traykov L, Caputo L et al. The apolipoprotein E epsilon 4 allele and the response to tacrine therapy in Alzheimer’s disease. Eur J Neurol 2000; 7:255-8.

Rigaud AS, Traykov L, Latour F, Couderc R, Moulin F, Forette F. Presence of absence of least one epsilon 4 allele and gender are not predictive for the response to donepezil treatment in Alzheimer’s disease. Pharmacogenetics 2002; 12:415-20.

Rigel DF, Fu F, Beil M, Hu CW, Liang G, Jeng AY. Pharmacodynamic and pharmacokinetic characterization of the aldosterone synthase inhibitor FAD286 in two rodent models of hyperaldosteronism: comparison with the 11beta-hydroxylase inhibitor metyrapone. J Pharmacol Exp Ther 2010; 334:232-43.

Rihs HP, Pesch B, Kappler M et al. Occupational exposure to polycyclic aromatic hydrocarbons in German industries: association between exogenous exposure and urinary metabolites and its modulation by enzyme polymorphisms. Toxicol Lett 2005; 157:241-55.

Rihs HP, Spickenheuer A, Heinze E et al. Modulation of urinary polycyclic aromatic hydrocarbon metabolites by enzyme polymorphisms in workers of the German Human Bitumen Study. Arch Toxicol 2011; 85 Suppl 1:73-9.

Rijavec M, Silar M, Triller N et al. Expressions of topoisomerase IIα and BCRP in metastatic cells are associated with overall survival in small cell lung cancer patients. Pathol Oncol Res 2011; 17:691-6.

Riksen NP, Franke B, van den Broek P, Smits P, Rongen GA. The 1976C>T polymorphism in the adenosine A2A receptor gene does not affect the vasodilator response to adenosine in humans in vivo. Pharmacogenet Genomics 2007; 17:551-4.

Riley KP, Jicha GA, Davis D et al. Prediction of preclinical Alzheimer’s disease: longitudinal rates of change in cognition. J Alzheimers Dis 2011; 25:707-17.

Riley RJ, Howbrook D. In vitro analysis of the activity of the major human hepatic CYP enzyme (CYP3A4) using [N-methyl-14C]-erythromycin. J Pharmacol Toxicol Methods 1997; 38:189-93.

Riley RJ, Parker AJ, Trigg S, Manners CN. Development of a generalized, quantitative physicochemical model of CYP3A4 inhibition for use in early drug discovery. Pharm Res 2001; 18:652-5.

Rimmerman N, Juknat A, Kozela E, Levy R, Bradshaw HB, Vogel Z. The non-psychoactive plant cannabinoid, cannabidiol affects cholesterol metabolism-related genes in microglial cells. Cell Mol Neurobiol 2011; 31:921-30.

Rinder CS, Mathew JP, Rinder HM et al. Platelet PlA2 polymorphism and platelet activation are associated with increased troponin I release after cardiopulmonary bypass. Anesthesiology 2002; 97:1118-22.

Ring BJ, Binkley SN, Vandenbranden M, Wrighton SA. In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A. Br J Clin Pharmacol 1996; 41:181-6.

Ring BJ, Eckstein JA, Gillespie JS, Binkley SN, VandenBranden M, Wrighton SA. Identification of the human cytochromes p450 responsible for in vitro formation of R- and S-norfluoxetine. J Pharmacol Exp Ther 2001; 297:1044-50.

Ring BJ, Gillespie JS, Binkley SN, Campanale KM, Wrighton SA. The interactions of a selective protein kinase C beta inhibitor with the human cytochromes P450. Drug Metab Dispos 2002; 30:957-61.

Ringel J, Beige J, Kunz R, Distler A, Sharma AM. Genetic variants of the renin-angiotensin system, diabetic nephropathy and hypertension. Diabetologia 1997; 40:193-9.

Riordan JR, Deuchars K, Kartner N, Alon N, Trent J, Ling V. Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines. Nature 1985; 316:817-9.

Ríos DL, Cerqueira CC, Bonfim-Silva R et al. Interleukin-1 beta and interleukin-6 gene polymorphism associations with angiographically assessed coronary artery disease in Brazilians. Cytokine 2010; 50:292-6.

Ripp SL, Mills JB, Fahmi OA et al. Use of immortalized human hepatocytes to predict the magnitude of clinical drug-drug interactions caused by CYP3A4 induction. Drug Metab Dispos 2006; 34:1742-8.

Risinger AL, Westbrook CD, Encinas A et al. ELR510444, a novel microtubule disruptor with multiple mechanisms of action. J Pharmacol Exp Ther 2011; 336:652-60.

Risio M, Venesio T, Kolomoets E et al. Genetic polymorphisms of CYP17A1, vitamin D receptor and androgen receptor in Italian heredo-familial and sporadic prostate cancers. Cancer Epidemiol 2011; 35:18-24.

Risselada AJ, Vehof J, Bruggeman R et al. Association between HTR2C gene polymorphisms and the metabolic syndrome in patients using antipsychotics: a replication study. Pharmacogenomics J 2010. doi:10. 1038/tpj. 2010. 66.

Ristoff E, Larsson A. Inborn errors in the metabolism of glutathione. Orphanet J Rare Dis 2007; 2:16.

Ristow M, Müller-Wieland D, Pfeiffer A, Krone W, Kahn CR. Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. N Engl J Med 1998; 339:953-9.

Ritchie K, Ancelin ML, Beaino E et al. Retrospective identification and characterization of mild cognitive impairment from a prospective population cohort. Am J Geriatr Psychiatry 2010; 18:692-700.

Ritchie MD, Haas DW, Motsinger AA et al. Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity. Clin Infect Dis 2006; 43:779-82.

Ritchie TJ, Macdonald SJ. The impact of aromatic ring count on compound developability-are too many aromatic rings a liability in drug design? Drug Discov Today 2009; 14:1011-20.

Rittenbach KA, Baker GB. Involvement of cytochromes P450 2D6, 2B6 and 2C19 in the metabolism of (-)-deprenyl and N-methyl,N-propargylphenylethylamine. Drug Metab Lett 2007; 1:97-100.

Rittenbach KA, Holt A, Ling L, Shan J, Baker GB. Metabolism of N-methyl, N-propargylphenylethylamine: studies with human liver microsomes and cDNA expressed cytochrome P450 (CYP) enzymes. Cell Mol Neurobiol 2007; 27:179-90.

Ritter JK, Crawford JM, Owens IS. Cloning of two human liver bilirubin UDP-glucuronosyltransferase cDNAs with expression in COS-1 cells. J Biol Chem 1991; 266:1043-7.

Ritter JK, Chen F, Sheen YY et al. A novel complex locus UGT1 encodes human bilirubin, phenol, and other UDP-glucuronosyltransferase isozymes with identical carboxyl termini. J Biol Chem 1992; 267:3257-61.

Ritter JK, Sheen YY, Owens IS. Cloning and expression of human liver UDP-glucuronosyltransferase in COS-1 cells. 3,4-catechol estrogens and estriol as primary substrates. J Biol Chem 1990; 265:7900-6.

Ritter JK, Yeatman MT, Ferreira P, Owens IS. Identification of a genetic alteration in the code for bilirubin UDP-glucuronosyltransferase in the UGT1 gene complex of a Crigler-Najjar type I patient. J Clin Invest 1992; 90:150-5.

Ritter JK, Yeatman MT, Kaiser C, Gridelli B, Owens IS. A phenylalanine codon deletion at the UGT1 gene complex locus of a Crigler-Najjar type I patient generates a pH-sensitive bilirubin UDP-glucuronosyltransferase. J Biol Chem 1993; 268:23573-9.

Rittweger M, Arastéh K. Clinical pharmacokinetics of darunavir. Clin Pharmacokinet 2007; 46:739-56.

Rius M, Hummel-Eisenbeiss J, Keppler D. ATP-dependent transport of leukotrienes B4 and C4 by the multidrug resistance protein ABCC4 (MRP4). J Pharmacol Exp Ther 2008; 324:86-94.

Rivas A, Francis HW. Inner ear abnormalities in a Kcnq1 (Kvlqt1) knockout mouse: a model of Jervell and Lange-Nielsen syndrome. Otol Neurotol 2005; 26:415-24.

Rivella S, May C, Chadburn A, Rivière I, Sadelain M. A novel murine model of Cooley anemia and its rescue by lentiviral-mediated human beta-globin gene transfer. Blood 2003; 101:2932-9.

Rivera E. Implications of anthracycline-resistant and taxane-resistant metastatic breast cancer and new therapeutic options. Breast J 2010; 16:252-63.

Rivero O, Sanjuan J, Aguilar EJ et al. Serotonin transporter gene polymorphisms and auditory hallucinations in psychosis. Rev Neurol 2010; 50:325-32.

Rivory LP, Qin H, Clarke SJ et al. Frequency of cytochrome P450 3A4 variant genotype in transplant population and lack of association with cyclosporin clearance. Eur J Clin Pharmacol 2000; 56:395-8.

Rivory LP, Slaviero K, Seale JP et al. Optimizing the erythromycin breath test for use in cancer patients. Clin Cancer Res 2000; 6:3480-5.

Rizzo R, Spaggiari F, Indelli M et al. Association of CYP1B1 with hypersensitivity induced by taxane therapy in breast cancer patients. Breast Cancer Res Treat 2010; 124:593-8.

Rizzo S, Hersey JM, Mellor P et al. Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2. Mol Cancer Ther 2011; 10:325-35.

Rizzu P, Hinkle DA, Zhukareva V et al. DJ-1 colocalizes with tau inclusions: a link between parkinsonism and demetia. Ann Neurol 2004; 55:113-8.

Roach M 3rd, de Silvio M, Rebbick T et al. Racial differences in CYP3A4 genotype and survival among men treated on Radiation Therapy Oncology Group (RTOG) 9202: a phase III randomized trial. Int J Radiat Oncol Biol Phys 2007; 69:79-87.

Robakis NK, Devine-Gage EA, Jenkis EC et al. Localization of a human gene homologous to the PrP gene on the p arm of chromosome 20 and detection of PrP-related antigens in normal human brain. Biochem Biophys Res Commun 1986; 140:758-65.

Robbiani DF, Finch RA, Jager D, Muller WA, Sartorelli AC, Randolph GJ. The leukotriene C4 transporter MRP1 regulates CCL19 (MIP-3-beta, ELC)-dependent mobilization of dendritic cells to lymph nodes. Cell 2000; 103:757-68.

Robbins MG, Andersen G, Somoza V, Eshelman BD, Barnes DM, Hanlon PR. Heat treatment of Brussels sprouts retains their ability to induce detoxification enzyme expression in vitro and in vivo. J Food Sci 2011; 76:454-61.

Robbins MG, Hauder J, Somoza V, Eshelman BD, Barnes DM, Hanlon PR. Induction of detoxification enzymes by feeding unblanched Brussels sprouts containing active myrosinase to mice for 2 wk. J Food Sci 2010; 75:190-9.

Robert M, Salvà M, Segarra R et al. The prokinetic cinitapride has no clinically relevant pharmacokinetic interaction and effect on QT during coadministration with ketoconazole. Drug Metab Dispos 2007; 35:1149-56.

Robert Schnatter A, Kerzic PJ, Zhou Y et al. Peripheral blood effects in benzene-exposed workers. Chem Biol Interact 2010; 184:174-81.

Roberts AG, Atkins WM. Energetics of heterotropic cooperativity between alpha-naphthoflavone and testosterone binding to CYP3A4. Arch Biochem Biophys 2007; 463:89-101.

Roberts AG, Campbell AP, Atkins WM. The thermodynamic landscape of testosterone binding to cytochrome P450 3A4: ligand binding and spin state equilibria. Biochemistry 2005; 44:1353-66.

Roberts BJ, Knights KM. Inhibition of rat peroxisomal palmitoyl-CoA ligase by xenobiotic carboxylic acids. Biochem Pharmacol 1992; 44:261-7.

Roberts JD, Smith MR, Feldman EJ et al. Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin’s) lymphoma. Clin Cancer Res 2006; 12:5809-16.

Roberts LM, Woodford K, Zhou M et al. Expression of the thyroid hormone transporters monocarboxylate transporter-8 (SLC16A2) and organic ion transporter-14 (SLCO1C1) at the blood-brain barrier. Endocrinology 2008; 149:6251-61.

Roberts RL, Gearry RB, Bland MV et al. Trinucleotide repeat variants in the promoter of the thiopurine S-methyltransferase gene of patients exhibiting ultra-high enzyme activity. Pharmacogenetics and Genomics 2008; 5:434-8.

Roberts RL, Joyce PR, Mulder RT, Begg EJ, Kennedy MA. A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression. Pharmacogenomics J 2002; 2:191-6.

Roberts RL, Mulder RT, Joyce PR, Luty SE, Kennedy MA. No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline. Hum Psychopharmacol 2004; 19:17-23.

Robertson GR, Field J, Goodwin B et al. Transgenic mouse models of human CYP3A4 gene regulation. Mol Pharmacol 2003; 64:42-50.

Robertson GR, Liddle C, Clarke SJ. Inflammation and altered drug clearance in cancer: transcriptional repression of a human CYP3A4 transgene in tumor-bearing mice. Clin Pharmacol Ther 2008; 83:894-7.

Robertson P Jr, Hellriegel ET, Arora S, Nelson M. Effect of modafinil on the pharmacokinetics of ethinyl estradiol and triazolam in healthy volunteers. Clin Pharmacol Ther 2002; 71:46-56.

Robertson P Jr, Hellriegel ET. Clinical pharmacokinetic profile of modafinil. Clin Pharmacokinet 2003; 42:123-37.

Robertson P, DeCory HH, Madan A, Parkinson A. In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil. Drug Metab Dispos 2000; 28:664-71.

Robertson SM, Davey RT, Voell J, Formentini E, Alfaro RM, Penzak SR. Effect of Ginkgo biloba extract on lopinavir, midazolam and fexofenadine pharmacokinetics in healthy subjects. Curr Med Res Opin 2008; 24:591-9.

Robertson SM, Maldarelli F, Natarajan V, Formentini E, Alfaro RM, Penzak SR. Efavirenz induces CYP2B6-mediated hydroxylation of bupropion in healthy subjects. J Acquir Immune Defic Syndr 2008; 49:513-9.

Robey RW, Honjo Y, Morisaki K et al. Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity. Br J Cancer 2003; 89:1971-8.

Robey RW, Ierano C, Zhan Z, Bates SE. The challenge of exploiting ABCG2 in the clinic. Curr Pharm Biotechnol 2011; 12:595-608.

Robey RW, Polgar O, Deeken J, To KW, Bates SE. ABCG2: determining its relevance in clinical drug resistance. Cancer Metastasis Rev 2007; 26:39-57.

Robey RW, Shukla S, Finley EM et al. Inhibition of P-glycoprotein (ABCB1)-and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)). Biochem Pharmacol 2008; 75:1302-12.

Robinson DM, Curran MP, Lyseng-Williamson KA. Imidapril: a review of its use in essential hypertension, Type 1 diabetic nephropathy and chronic heart failure. Drugs 2007; 67:1359-78.

Robinson J, Waller MJ, Fail SC, Marsh SG. The IMGT/HLA and IPD databases. Hum Mutat 2006; 27:1192-9.

Robinson JD, Lam CY, Minnix JA et al. The DRD2 TaqI-B polymorphism and its relationship to smoking abstinence and withdrawal symptoms. Pharmacogenomics J 2007; 7:266-74.

Robinson JG. Simvastatin: present and future perspectives. Expert Opin Pharmacother 2007; 8:2159-27.

Robinson JP, Johnson VL, Rogers PA et al. Evidence for an association between compound heterozygosity for germ line mutations in the hemochromatosis (HFE) gene and increased risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 2005; 14:1460-3.

Robinson M, Williams SM. Role of two angiotensinogen polymorphisms in blood pressure variation. J Hum Hypertens 2004; 18:865-9.

Robitaille J, Brouillette C, Houde A et al. Association between the PPARalpha-L162V polymorphism and components of the metabolic syndrome. J Hum Genet 2004; 49:482-9.

Robitaille J, Brouillette C, Lemieux S, Pérusse L, Gaudet D, Vohl MC. Plasma concentrations of apolipoprotein B are modulated by a gene-diet interaction effect between the LFABP T94A polymorphism and dietary fat intake in French-Canadian men. Mol Genet Metab 2004; 82:296-303.

Roby CA, Anderson GD, Kantor E, Dryer DA, Burstein AH. St John’s Wort: effect on CYP3A4 activity. Clin Pharmacol Ther 2000; 67:451-7.

Roca B. Pharmacogenomics of antiretrovirals. Recent Pat Antiinfect Drug Discov 2008; 3:132-5.

Rocco DD, Okuda LS, Pinto RS et al. Aerobic exercise improves reverse cholesterol transport in cholesteryl ester transfer protein transgenic mice. Lipids 2011; 46:617-25.

Rock EP, Goodman V, Jiang JX et al. Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist 2007; 12:107-13.

Rockenstein E, Mante M, Adame A, Crews L, Moessler H, Masliah E. Effects of cerebrolysin on neurogenesis in an APP transgenic model of Alzheimer’s disease. Acta Neuropathol 2007; 113:265-75.

Röckl KS, Witczak CA, Goodyear LJ. Signaling mechanisms in skeletal muscle: acute responses and chronic adaptations to exercise. IUBMB Life 2008; 60:145-53.

Rocha A, Coelho EB, Lanchote VL. Influence of quinidine, fluvoxamine, and ketoconazole on the enantioselective pharmacokinetics of citalopram in rats. Can J Physiol Pharmacol 2008; 86:770-6.

Rocha A, Coelho EB, Sampaio SA, Lanchote VL. Omeprazole preferentially inhibits the metabolism of (+)-(S)-citalopram in healthy volunteers. Br J Clin Pharmacol 2010; 70:43-51.

Rocha AM, de Souza C, Rocha GA et al. IL1RN VNTR and IL2-330 polymorphic genes are independently associated with chronic immune thrombocytopenia. Br J Haematol 2010; 150:679-84.

Rocha GD, Simões M, Oliveira RR, Kaplan MA, Gattass CR. 3beta-acetyl tormentic acid induces apoptosis of resistant leukemia cells independently of P-gp/ABCB1 activity or expression. Invest New Drugs 2010. doi:10. 1007/s10637-010-9524-1.

Rochais F, Vilardaga JP, Nikolaev VO, Bünemann M, Lohse MJ, Engelhardt S. Real-time optical recording of beta1-adrenergic receptor activation reveals supersensitivity of the Arg389 variant to carvedilol. J Clin Invest 2007; 117:229-35.

Rochat B, Amey M, Gillet M, Meyer UA, Baumann P. Identification of three cytochrome P450 isozymes involved in N-demethylation of citalopram enantiomers in human liver microsomes. Pharmacogenetics 1997; 7:1-10.

Rochat B, Zoete V, Grosdidier A, von Grünigen S, Marull M, Michielin O. In vitro biotransformation of imatinib by the tumor expressed CYP1A1 and CYP1B1. Biopharm Drug Dispos 2008; 29:103-18.

Rochira V, Zirilli L, Maffei L et al. Tall stature without growth hormone: four male patients with aromatase deficiency. J Clin Endocrinol Metab 2010; 95:1626-33.

Roddier K, Thomas T, Marleau G et al. Two mutations in the HSN2 gene explain the high prevalence of HSAN2 in French Canadians. Neurology 2005; 64:1762-7.

Rodenburg EM, Visser LE, Danser AH et al. Genetic variance in CYP2C8 and increased risk of myocardial infarction. Pharmacogenet Genomics 2010; 20:426-34.

Roder HM, Hutton ML. Microtubule-associated protein tau as a therapeutic target in neurodegenerative disease. Expert Opin Ther Targets 2007; 11:435-42.

Rodondi N, Darioli R, Ramelet AA et al. High risk for hyperlipidemia and the metabolic syndrome after an episode of hypertriglyceridemia during 13-cis retinoic acid therapy for acne: apharmacogenetic study. Ann Intern Med 2002; 136:582-9.

Rodrigues AC, Curi R, Genvigir FD, Hirata MH, Hirata RD. The expression of efflux and uptake transporters are regulated by statins in Caco-2 and HepG2 cells. Acta Pharmacol Sin 2009; 30:956-64.

Rodrigues AD. Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochem Pharmacol 1999; 57:465-80

Rodrigues AD. Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same? Drug Metab Dispos 2005; 33:1567-75.

Rodrigues AD. Prioritization of clinical drug interaction studies using in vitro cytochrome P450 data: proposed refinement and expansion of the “rank order” approach. Drug Metab Lett 2007; 1:31-5.

Rodrigues AD, Kukulka MJ, Roberts EM, Ouellet D, Rodgers TR. [O-methyl 14C]naproxen O-demethylase activity in human liver microsomes: evidence for the involvement of cytochrome P4501A2 and P4502C9/10. Drug Metab Dispos 1996; 24:126-36.

Rodrigues AD, Mulford DJ, Lee RD et al. In vitro metabolism of terfenadine by a purified recombinant fusion protein containing cytochrome P4503A4 and NADPH-P450 reductase. Comparison to human liver microsomes and precision-cut liver tissue slices. Drug Metab Dispos 1995; 23:765-75.

Rodrigues AD, Roberts EM, Mulford DJ, Yao Y, Ouellet D. Oxidative metabolism of clarithromycin in the presence of human liver microsomes. Major role for the cytochrome P4503A (CYP3A) subfamily. Drug Metab Dispos 1997; 25:623-30.

Rodrigues IS, Kuasne H, Losi-Guembarovski R et al. Evaluation of the influence of polymorphic variants CYP1A1*2B, CYP1B1*2, CYP3A4*1B, GSTM1*0, and GSTT1*0 in prostate cancer. Urol Oncol 2010. doi:10. 1016/j. urolonc. 2010. 01. 009.

Rodriguez BA, Cheng AS, Yan PS et al. Epigenetic repression of the estrogen-regulated Homeobox B13 gene in breast cancer. Carcinogenesis 2008; 29:1459-65.

Rodriguez S, Cook DG, Gaunt TR, Nightingale CM, Whincup PH, Day IN. Combined analysis of CHRNA5, CHRNA3 and CYP2A6 in relation to adolescent smoking behaviour. J Psychopharmacol 2011; 25:915-23.

Rodriguez S, Gaunt TR, Day IN. Molecular genetics of human growth hormone, insulin-like growth factors and their pathways in common disease. Hum Genet 2007; 122:1-21.

Rodríguez-Antona C, Bort R, Jover R et al. Transcriptional regulation of human CYP3A4 basal expression by CCAAT enhancer-binding protein alpha and hepatocyte nuclear factor-3 gamma. Mol Pharmacol 2003; 63:1180-9.

Rodríguez-Antona C, Donato MT, Pareja E, Gómez-Lechón MJ, Castell JV. Cytochrome P-450 mRNA expression in human liver and its relationship with enzyme activity. Arch Biochem Biophys 2001; 393:308-15.

Rodríguez-Antona C, Gurwitz D, de Leon J et al. CYP2D6 genotyping for psychiatric patients treated with risperidone: considerations for cost-effectiveness studies. Pharmacogenomics 2009; 10:685-99.

Rodríguez-Antona C, Ingelman-Sundberg M. Cytochrome P450 pharmacogenetics and cancer. Oncogen 2006; 25:1679-91.

Rodríguez-Antona C, Leskelä S, Zajac M et al. Expression of CYP3A4 as a predictor of response to chemotherapy in peripheral T-cell lymphomas. Blood 2007; 110:3345-51.

Rodríguez-Antona C, Niemi M, Backman JT et al. Characterization of novel CYP2C8 haplotypes and their contribution to paclitaxel and repaglinide metabolism. Pharmacogenomics J 2008; 8:268-77.

Rodríguez-Antona C, Sayi JG, Gustafsson LL, Bertilsson L, Ingelman-Sundberg M. Phenotype-genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles. Biochem Biophys Res Commun 2005; 338:299-305.

Rodríguez-Nóvoa S, Barreiro P, Jiménez-Nácher I, Soriano V. Overview of the pharmacogenetics of HIV therapy. Pharmacogenomics J 2006; 6:234-45.

Rodríguez-Nóvoa S, Labarga P, Soriano V et al. Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis 2009; 48:108-16.

Rodríguez-Nóvoa S, Labarga P, Soriano V. Pharmacogenetics of tenofovir treatment. Pharmacogenomics 2009; 10:1675-85.

Rodríguez-Ortigosa CM, Banales JM, Olivas I et al. Biliary secretion of S-nitrosoglutathione is involved in the hypercholeresis induced by ursodeoxycholic acid in the normal rat. Hepatology 2010; 52:667-77.

Rodriguez-Perez AI, Valenzuela R, Villar-Cheda B, Guerra MJ, Lanciego JL, Labandeira-Garcia JL. Estrogen and angiotensin interaction in the substantia nigra. Relevance to postmenopausal Parkinson’s disease. Exp Neurol 2010; 224:517-26.

Rodríguez-Pérez JC, Rodríguez-Esparragón F, Hernández-Perera O et al. Association of angiotensinogen M235T and A(-6)G gene polymorphisms with coronary heart disease with independence of essential hypertension: the PROCAGENE study. Prospective Cardiac Gene. J Am Coll Cardiol 2001; 37:1536-42.

Rodríguez-Rodríguez E, Mateo I, Infante J et al. Interaction between HMGCR and ABCA1 cholesterol-related genes modulates Alzheimer’s disease risk. Brain Res 2009; 1280:166-71.

Rodríguez-Rodríguez E, Vázquez-Higuera JL, Sánchez-Juan P et al. Epistasis between intracellular cholesterol trafficking-related genes (NPC1 and ABCA1) and Alzheimer’s disease risk. J Alzheimers Dis 2010; 21:619-25.

Rodríguez-Santiago B, Brunet A, Sobrino B et al. Association of common copy number variants at the glutathione S-transferase genes and rare novel genomic changes with schizophrenia. Mol Psychiatry 2010; 15:1023-33.

Rodriguez-Viciana P, Tetsu O, Tidyman WE et al. Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome. Science 2006; 311:1287-90.

Roe MA, Heath AL, Oyston SL et al. Iron absorption in male C282Y heterozygotes. Am J Clin Nutr 2005; 81:814-21.

Roecker AM, Allison JC, Kisor DF. Nelarabine: efficacy in the treatment of clinical malignancies. Future Oncol 2006; 2:441-8.

Roedler R, Neuhauser MM, Penzak SR. Does metronidazole interact with CYP3A substrates by inhibiting their metabolism through this metabolic pathway? Or should other mechanisms be considered? Ann Pharmacother 2007; 41:653-8.

Roepke TK, King EC, Reyna-Neyra A et al. Kcne2 deletion uncovers its crucial role in thyroid hormone biosynthesis. Nat Med 2009; 15:1186-94.

Roffman JL, Weiss AP, Purcell S et al. Contribution of methylenetetrahydrofolate reductase (MTHFR) polymorphisms to negative symptoms in schizophrenia. Biol Psychiatry 2008; 63:42-8.

Rogaev EI, Lukiw WJ, Vaula G et al. Analysis of the c-FOS gene on chromosome 14 and the promoter of the amyloid precursor protein gene in familial Alzheimer’s disease. Neurology 1993; 43:2275-9.

Rogalski EJ, Rademaker A, Harrison TM et al. ApoE E4 is a susceptibility factor in amnestic but not aphasic dementias. Alzheimer Dis Assoc Disord 2011; 25:159-63.

Rögelsperger O, Wlcek K, Ekmekcioglu C et al. Melatonin receptors, melatonin metabolizing enzymes and cyclin D1 in human breast cancer. J Recept Signal Transduct Res 2011; 31:180-7.

Rogers AJ, Tantisira KG, Fuhlbrigge AL et al. Predictors of poor response during asthma therapy differ with definition of outcome. Pharmacogenomics 2009; 10:1231-42.

Rogers JD, Zhao J, Liu L et al. Grapefruit juice has minimal effects on plasma concentrations of lovastatin-derived 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Clin Pharmacol Ther 1999; 66:358-66.

Rogers PJ, Hohoff C, Heatherley SV et al. Association of the anxiogenic and alerting effects of caffeine with ADORA2A and ADORA1 polymorphisms and habitual level of caffeine consumption. Neuropsychopharmacology 2010; 35:1973-83.

Roglans N, Bellido A, Rodríguez C et al. Fibrate treatment does not modify the expression of acyl coenzyme A oxidase in human liver. Clin Pharmacol Ther 2002; 72:692-701.

Rogus JJ, Moczulski D, Freire MB, Yang Y, Warram JH, Krolewski AS. Diabetic nephropathy is associated with AGT polymorphism T235: results of a family-based study. Hypertension 1998; 31:627-31.

Roh HK, Chung JY, Oh DY et al. Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients. Br J Clin Pharmacol 2001; 52:265-71.

Roh HK, Kim CE, Chung WG, Park CS, Svensson JO, Bertilsson L. Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients. Eur J Clin Pharmacol 2001; 57:671-5.

Rohatagi S, Barrett JS, Sawyers W, Yu K, Morales RJ. Pharmacokinetics of ipriflavone and metabolites after oral administration of a corn-oil suspension relative to the Osteofix tablet. Am J Ther 1997; 4:229-38.

Rohatagi S, Gillen M, Aubeneau M et al. Effect of age and gender on the pharmacokinetics of ebastine after single and repeated dosing in healthy subjects. Int J Clin Pharmacol Ther 2001; 39:126-34.

Rohrbacher M, Kirchhof A, Skarke C, Geisslinger G, Lötsch J. Rapid identification of three functionally relevant polymorphisms in the OATP1B1 transporter gene using Pyrosequencing. Pharmacogenomics 2006; 2:167-76.

Rojas J, Fernandez I, Pastor JC et al. A strong genetic association between the tumor necrosis factor locus and proliferative vitreoretinopathy: the retina 4 project. Ophthalmology 2010; 117:2417-23.

Rokavec M, Schroth W, Amaral SM et al. A polymorphism in the TC21 promoter associates with an unfavorable tamoxifen treatment outcome in breast cancer. Cancer Res 2008; 68:9799-808.

Rolan P, Sargentini-Maier ML, Pigeolet E, Stockis A. The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men. Br J Clin Pharmacol 2008; 66:71-5.

Rollason V, Samer C, Piguet V, Dayer P, Desmeules J. Pharmacogenetics of analgesics: toward the individualization of prescription. Pharmacogenomics 2008; 9:905-33.

Rollema H, Shrikhande A, Ward KM et al. Pre-clinical properties of the alpha4beta2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence. Br J Pharmacol 2010; 160:334-45.

Romagnoli P, Bron C. Defective TCR signaling events in glycosylphosphatidylinositol-deficient T cells derived from paroxysmal nocturnal hemoglobinuria patients. Int Immunol 1999; 11:1411-22.

Roman T, Polanczyk GV, Zeni C, Genro JP, Rohde LA, Hutz MH. Further evidence of the involvement of alpha-2A-adrenergic receptor gene (ADRA2A) in inattentive dimensional scores of attention-deficit/hyperactivity disorder. Molec Psychiat 2006; 11:8-10.

Roman T, Schmitz M, Polanczyk GV, Eizirik M, Rhode LA, Hutz MH. Is the alpha-2A adrenergic receptor gene (ADRA2A) associated with attention-deficit/hyperactivity disorder? Am J Med Genet 2003; 120:116-20.

Romanatto T, Roman EA, Arruda AP et al. Deletion of tumor necrosis factor-alpha receptor 1 (TNFR1) protects against diet-induced obesity by means of increased thermogenesis. J Biol Chem 2009; 284:36213-22.

Romano M, Claria J. Cyclooxygenase-2 and 5-lipoxygenase converging functions on cell proliferation and tumor angiogenesis: implications for cancer therapy. FASEB J 2003; 17:1986-95.

Romberg RR, Olofsen E, Bijl H et al. Polymorphism of mu-opioid receptor gene (OPRM1:c. 118A>G) does not protect against opioid-induced respiratory depression despite reduced analgesic response. Anesthesiology 2005; 102:522-30.

Romeo G, Hassan HJ, Staempfli S et al. Hereditary thrombophilia: identification of nonsense and missense mutations in the protein C gene. Proc Natl Acad Sci USA 1987; 84:2829-32.

Romero DG, Gomez-Sanchez EP, Gomez-Sanchez CE. Angiotensin II-regulated transcription regulatory genes in adrenal steroidogenesis. Physiol Genomics 2010; 42:259-66.

Romero-Zerbo Y, Decara J, el Bekay R et al. Protective effects of melatonin against oxidative stress in Fmr1 knockout mice: a therapeutic research model for the fragile X syndrome. J Pineal Res 2009; 46:224-34.

Romkes M, Chern HD, Lesnick TG et al. Association of low CYP3A activity with p53 mutation and CYP2D6 activity with Rb mutation in human bladder cancer. Carcinogenesis 1996; 17:1057-62.

Romkes M, Faletto MB, Blaisdell JA, Raucy JL, Goldstein JA. Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily. Biochemistry 1991; 30:3247-55.

Ronaldson PT, Ashraf T, Bendayan R. Regulation of multidrug resistance protein 1 by tumor necrosis factor alpha in cultured glial cells: involvement of nuclear factor-kappaB and c-Jun N-terminal kinase signaling pathways. Mol Pharmacol 2010; 77:644-59.

Rong G, Jing L, Deng-Qing L, Hong-Shan Z, Shai-Hong Z, Xin-Min N. Influence of CYP3A5 and MDR1(ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in Chinese renal transplant recipients. Transplant Proc 2010; 42:3455-8.

Rong W, Winchester WJ, Grundy D. Spontaneous hypersensitivity in mesenteric afferent nerves of mice deficient in the sst2 subtype of somatostatin receptor. J Physiol 2007; 581:779-86.

Rontu R, Lehtimäki T, Ilveskoski E et al. Association of paraoxonase-1 M55L genotype and alcohol consumption with coronary atherosclerosis: the Helsinki Sudden Death Study. Pharmacogenetics 2004; 14:479-85.

Rooryck C, Barnetche T, Richez C, Laleye A, Arveiler B, Schaeverbeke T. Influence of FCGR3A-V212F and TNFRSF1B-M196R genotypes in patients with rheumatoid arthritis treated with infliximab therapy. Clin Exp Rheumatol 2008; 26:340-2.

Roos PH, Belik R, Föllmann W et al. Expression of cytochrome P450 enzymes CYP1A1, CYP1B1, CYP2E1 and CYP4B1 in cultured transitional cells from specimens of the human urinary tract and from urinary sediments. Arch Toxicol 2006; 80:45-52.

Roos R, Andersson PL, Halldin K et al. Hepatic effects of a highly purified 2,2’,3,4,4’,5,5’-heptachlorbiphenyl (PCB 180) in male and female rats. Toxicology 2011; 284:42-53.

Rooyen JM, Pretorius PJ, Britz M et al. Genetic polymorphisms of beta2- and beta3-adrenergic receptor genes associated with characteristics of the metabolic syndrome in black South African women. Exp Clin Endocrinol Diabetes 2008; 116:236-40.

Rordorf CM, Choi L, Marshall P, Mangold JB. Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet 2005; 44:1247-66.

Rosales C, Tang D, Gillard BK, Courtney HS, Pownall HJ. Apolipoprotein E mediates enhanced plasma high-density lipoprotein cholesterol clearance by low-dose streptococcal serum opacity factor via hepatic low-density lipoprotein receptors in vivo. Arterioscler Thromb Vasc Biol 2011; 31:1834-41.

Rosatelli MC, Meloni A, Faa V et al. Molecular analysis of patients of Sardinian descent with Crigler-Najjar syndrome type I. J Med Genet 1997; 34:122-5.

Rosell R, Moran T, Queralt C et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009; 361:958-67.

Rosell R, Taron M, Camps C, López-Vivanco G. Influence of genetic markers on survival in non-small cell lung cancer. Drugs Today 2003; 39:775-86.

Rosen H. Dextromethorphan/quinidine sulfate for pseudobulbar affect. Drugs Today 2008; 44:661-8.

Rosen MB, Schmid JR, Corton JC et al. Gene expression profiling in wild-type and PPARα-Null mice exposed to perfluorooctane sulfonate reveals PPARα-independent effects. PPAR Res 2010. doi:10. 1155/2010/794739.

Rosenbaum DM, Cherezov V, Hanson MA et al. GPCR engineering yields high-resolution structural insights into beta-2-adrenergic receptor function. Science 2007; 318:1266-73.

Rosenberg MF, Bikadi Z, Chan J et al. The human breast cancer resistance protein (BCRP/ABCG2) shows conformational changes with mitoxantrone. Structure 2010; 18:482-93.

Rosenberg MF, Oleschuk CJ, Wu P, Mao Q, Deeley RG, Cole SP, Ford RC. Structure of a human multidrug transporter in an inward-facing conformation. J Struct Biol 2010; 170:540-7.

Rosenberry TL, Sonoda LK, Dekat SE, Cusack B, Johnson JL. Analysis of the reaction of carbachol with acetylcholinesterase using thioflavin T as a coupled fluorescence reporter. Biochemistry 2008; 47:13056-63.

Rosenblatt A, Brinkman RR, Liang KY et al. Familial influences on age of onset among siblings with Huntington disease. Am J Med Genet 2001; 105:399-403.

Rosenborg S, Stenberg M, Otto S et al. Clinically significant CYP2C inhibition by noscapine but not by glucosamine. Clin Pharmacol Ther 2010; 88:343-6.

Rosenfeld RG. Pharmacogenomics and pharmacoproteomics in the evaluation and management of short stature. Eur J Endocrinol 2007; 157 Suppl 1:27-31.

Rosengren AH, Jokubka R, Tojjar D et al. Overexpression of alpha2A-adrenergic receptors contributes to type 2 diabetes. Science 2010; 327:217-20.

Rosenquist TA, Einolf HJ, Dickman KG, Wang L, Smith A, Grollman AP. Cytochrome P450 1A2 detoxicates aristolochic acid in the mouse. Drug Metab Dispos 2010; 38:761-8.

Roses AD. Pharmacogenetics and drug development: the path to safer and more effective drugs. Nat Rev Genet 2004; 5:645-56.

Roses AD. Pharmacogenetics in drug discovery and development: a translational perspective. Nat Rev Drug Discov 2008; 7:807-17.

Roses AD, Saunders AM, Huang Y, Strum J, Weisgraber KH, Mahley RW. Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer’s disease). Pharmacogenomics J 2007; 7:10-28.

Roses AD, Strittmatter WJ, Pericak-Vance MA, Corder EH, Saunders AM, Schmechel DE. Clinical application of apolipoprotein E genotyping to Alzheimer’s disease. Lancet 1994; 343:1564-5.

Rosman DS, Kaklamani V, Pasche B. New insights into breast cancer genetics and impact on patient management. Curr Treat Options Oncol 2007; 8:61-73.

Rosmond R, Bouchard C, Björntorp P. Allelic variants in the GABA(A)alpha6 receptor subunit gene (GABRA6) is associated with abdominal obesity and cortisol secretion. Int J Obes Relat Metab Disord 2002; 26:938-41.

Ross D. Functions and distribution of NQO1 in human bone marrow: potential clues to benzene toxicity. Chem Biol Interact 2005; 153-154:137-46.

Ross JA, Oeffinger KC, Davies SM et al. Genetic variation in the leptin receptor gene and obesity in survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2004; 22:3558-62.

Ross JR, Riley J, Taegetmeyer AB et al. Genetic variation and response to morphine in cancer patients: catechol-O-methyltransferase and multidrug resistance-1 gene polymorphisms are associated with central side effects. Cancer 2008; 112:1390-403.

Ross JS. Multigene classifiers, prognostic factors, and predictors of breast cancer clinical outcome. Adv Anat Pathol 2009; 16:204-15.

Ross KA, Bigham AW, Edwards M, Gozdzik A, Suarez-Kurtz G, Parra EJ. Worldwide allele frequency distribution of four polymorphisms associated with warfarin dose requirements. J Hum Genet 2010; 55:582-9.

Ross ME, Zhou X, Song G et al. Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood 2003; 102:2951-9.

Rossi S, Gasparotto D, Toffolatti L et al. Molecular and clinicopathologic characterization of gastrointestinal stromal tumors (GISTs) of small size. Am J Surg Pathol 2010; 34:1480-91.

Rosskopf D, Kielbik M, Manthey I, Bilmen G, Eisenhardt A, Siffert W. Characterization of the splice variant Gbeta3v of the human G-protein Gbeta3 subunit. Biochim Biophys Acta 2003; 1626:33-42.

Rossman MD, Thompson B, Frederick M et al. HLA-DRB1*1101: a significant risk factor for sarcoidosis in blacks and whites. Am J Hum Genet 2003; 73:720-35.

Rosso Felipe C, de Sandes TV, Sampaio EL, Park SI, Silva HT Jr, Medina Pestana JO. Clinical impact of polymorphisms of transport proteins and enzymes involved in the metabolism of immunosuppressive drugs. Transplant Proc 2009; 41:1441-55.

Rosso SM, van Herpen E, Deelen W et al. A novel tau mutation S320F, causes a taupathy with inclusions similar to those in Pick’s disease. Ann Neurol 2002; 51:373-6.

Rossol M, Pierer M, Arnold S et al. Negative association of the chemokine receptor CCR5 d32 polymorphism with systemic inflammatory response, extra-articular symptoms and joint erosion in rheumatoid arthritis. Arthritis Res Ther 2009; 11:91.

Rost D, Kloeters-Plachky P, Stiehl A. Retrieval of the rat canalicular conjugate export pump Mrp2 is associated with a rearrangement of actin filaments and radixin in bile salt-induced cholestasis. Eur J Med Res 2008; 13:314-8.

Rost KL, Fuhr U, Thomsen T et al. Omeprazole weakly inhibits CYP1A2 activity in man. Int J Clin Pharmacol Ther 1999; 37:567-74.

Rost S, Fregin A, Hünerberg M, Bevans CG, Müller CR, Oldenburg J. Site-directed mutagenesis of coumarin-type anticoagulant-sensitive VKORC1: evidence that highly conserved amino acids define structural requirements for enzymatic activity and inhibition by warfarin. Thromb Haemost 2005; 94:780-6.

Rost S, Fregin A, Koch D, Compes M, Müller CR, Oldenburg J. Compound heterozygous mutations in the gamma-glutamyl carboxylase gene cause combined deficiency of all vitamin K-dependent blood coagulation factors. Br J Haematol 2004; 126:546-9.

Rostami-Hodjegan A, Wolff K, Hay AW, Raistrick D, Calvert R, Tucker GT. Population pharmacokinetics of methadone in opiate users: characterization of time-dependent changes. Br J Clin Pharmacol 1999; 48:43-52.

Roszkowska-Gancarz M, Kurylowicz A, Polosak J, Ambroziak M, Puzianowska-Kuznicka M. The -351A/G polymorphism of ESR1 is associated with risk of myocardial infarction but not with extreme longevity. Clin Chim Acta 2010; 411:1883-7.

Rota C, Rimbach G, Minihane AM, Stoecklin E, Barella L. Dietary vitamin E modulates differential gene expression in the rat hippocampus: potential implications for its neuroprotective properties. Nutr Neurosci 2005; 8:21-9.

Roten L, Schoenenberger RA, Krähenbühl S, Schlienger RG. Rhabdomyolysis in association with simvastatin and amiodarone. Ann Pharmacother 2004; 38:978-81.

Rotger M, Saumoy M, Zhang K et al. Partial deletion of CYP2B6 owing to unequal crossover with CYP2B7. Pharmacogenet Genomics 2007; 17:885-90.

Rotger M, Tegude H, Colombo S et al. Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin Pharmacol Ther 2007; 81:557-66.

Roth MJ, Wei WQ, Baer J et al. Aryl hydrocarbon receptor expression is associated with a family history of upper gastrointestinal tract cancer in a high-risk population exposed to aromatic hydrocarbons. Cancer Epidemiol Biomarkers Prev 2009; 18:2391-6.

Rothe HM, Shapiro WB, Sun WY, Chou SY. Calcium-sensing receptor gene polymorphism Arg990Gly and its possible effect on response to cinacalcet HCl. Pharmacogenet Genomics 2005; 15:29-34.

Rothman N, Smith MT, Hayes RB et al. Benzene poisoning, a risk factor for hematological malignancy, is associated with the NQO1 609C→T mutation and rapid fractional excretion of chlorzoxazone. Cancer Res 1997; 57:2839-42.

Rothweiler F, Michaelis M, Brauer P et al. Anticancer effects of the nitric oxide-modified saquinavir derivative saquinavir-NO against multidrug-resistant cancer cells. Neoplasia 2010; 12:1023-30.

Rotzinger S, Baker GB. Human CYP3A4 and the metabolism of nefazodone and hydroxynefazodone by human liver microsomes and heterologously expressed enzymes. Eur Neuropsychopharmacol 2002; 12:91-100.

Rotzinger S, Fang J, Baker GB. Trazodone is metabolized to m-chlorophenylpiperazine by CYP3A4 from human sources. Drug Metab Dispos 1998; 26:572-5.

Rouissi K, Stambouli N, Marrakchi R et al. Smoking and polymorphisms in folate metabolizing genes and their effects on the histological stage and grade for bladder tumors. Bull Cancer 2011; 98:1-10.

Rouits E, Boisdron-Celle M, Morel A, Gamelin E. Simple and sensitive high-performance liquid chromatography method for simultaneous determination of urinary free cortisol and 6beta-hydroxycortisol in routine practice. For CYP 3A4 activity evaluation in basal conditions and after grapefruit juice intake. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 793:357-66.

Rouits E, Charasson V, Pétain A et al. Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients. Br J Cancer 2008; 99:1239-45.

Roumen L, Peeters JW, Emmen JM, Beugels IP et al. Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem 2010; 53:1712-25.

Roumen L, van Hoof B, Pieterse K et al. Application of a ligand-based theoretical approach to derive conversion paths and ligand conformations in CYP11B2-mediated aldosterone formation. J Comput Chem 2011; 32:2441-8.

Roumier C, Cheok MH. Pharmacogenomics in acute myeloid leukemia. Pharmacogenomics 2009; 10:1839-51.

Roussel F, Khan KK, Halpert JR. The importance of SRS-1 residues in catalytic specificity of human cytochrome P450 3A4. Arch Biochem Biophys 2000; 374:269-78.

Rousselet E, Marcinkiewicz J, Kriz J et al. PCSK9 reduces the protein levels of the LDL receptor in mouse brain during development and after ischemic stroke. J Lipid Res 2011; 52:1383-91.

Rousset X, Vaisman B, Auerbach B et al. Effect of recombinant human lecithin cholesterol acyltransferase infusion on lipoprotein metabolism in mice. J Pharmacol Exp Ther 2010; 335:140-8.

Roussos P, Giakoumaki SG, Bitsios P. Cognitive and emotional processing in high novelty seeking associated with the L-DRD4 genotype. Neuropsychologia 2009; 47:1654-9.

Roustit M, Blondel E, Villier C, Fonrose X, Mallaret MP. Symptomatic hypoglycemia associated with trimethoprim/sulfamethoxazole and repaglinide in a diabetic patient. Ann Pharmacother 2010; 44:764-7.

Rouy S, Vidaud D, Alessandri JL et al. Prothrombin Saint-Denis: a natural variant with a point mutation resulting in Asp to Glu substitution at position 552 in prothrombin. Br J Haematol 2006; 132:770-3.

Rouzier C, Vanatka R, Bannwarth S et al. A novel homozygous MMP2 mutation in a family with Winchester syndrome. Clin Genet 2006; 69:271-6.

Rovio AT, Marchington DR, Donat S et al. Mutations at the mitochondrial DNA polymerase (POLG) locus associated with male infertility. Nat Genet 2001; 29:261-2.

Row E, Brown SA, Stachulski AV, Lennard MS. Development of novel furanocoumarin dimers as potent and selective inhibitors of CYP3A4. Drug Metab Dispos 2006; 34:324-30.

Row EC, Brown SA, Stachulski AV, Lennard MS. Design, synthesis and evaluation of furanocoumarin monomers as inhibitors of CYP3A4. Org Biomol Chem 2006; 4:1604-10.

Row EC, Brown SA, Stachulski AV, Lennard MS. Synthesis of 8-geranyloxypsoralen analogues and their evaluation as inhibitors of CYP3A4. Bioorg Med Chem 2006; 14:3865-71.

Rowan C, Brinker AD, Nourjah P et al. Rhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors. Pharmacoepidemiol Drug Saf 2009; 18:301-9.

Rowbotham SE, Boddy AV, Redfern CP, Veal GJ, Daly AK. Relevance of nonsynonymous CYP2C8 polymorphisms to 13-cis retinoic acid and paclitaxel hydroxylation. Drug Metab Dispos 2010; 38:1261-6.

Rowbotham SE, Illingworth NA, Daly AK, Veal GJ, Boddy AV. Role of UDP-glucuronosyltransferase isoforms in 13-cis retinoic acid metabolism in humans. Drug Metab Dispos 2010; 38:1211-7.

Rowe A, Narlawar R, Groundwater PW, Ramzan I. Kavalactone pharmacophores for major cellular drug targets. Mini Rev Med Chem 2011; 11:79-83.

Rowland K, Ellis SW, Lennard MS, Tucker GT. Variable contribution of CYP2D6 to the N-dealkylation of S-(-)-propranolol by human liver microsomes. Br J Clin Pharmacol 1996; 42:390-3.

Rowland Yeo K, Jamei M, Yang J, Tucker GT, Rostami-Hodjegan A. Physiologically based mechanistic modelling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut-The effect of diltiazem on the time-course of exposure to triazolam. Eur J Pharm Sci 2009; 39:298-309.

Rowlands CJ, Staskal DF, Gollapudi B, Budinsky R. The human AHR: identification of single nucleotide polymorphisms from six ethnic populations. Pharmacogenet Genomics 2010; 20:283-90.

Roy AK, Lavrovsky Y, Song CS et al. Regulation of androgen action. Vitam Horm 1999; 55:309-52.

Roy JN, Barama A, Poirier C, Vinet B, Roger M. Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients. Pharmacogenet Genomics 2006; 16:659-65.

Roy K, Pratim Roy P. Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques. Eur J Med Chem 2009; 44:2913-22.

Roy P, Tretyakov O, Wright J, Waxman DJ. Stereoselective metabolism of ifosfamide by human P-450s 3A4 and 2B6. Favorable metabolic properties of R-enantiomer. Drug Metab Dispos 1999; 27:1309-18.

Roy P, Yu LJ, Crespi CL, Waxman DJ. Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos 1999; 27:655-66.

Roy PP, Roy K. Molecular docking and QSAR studies of aromatase inhibitor androstenedione derivatives. J Pharm Pharmacol 2010; 62:1717-28.

Roy SK, Korzekwa KR, Gonzalez FJ, Moschel RC, Dolan ME. Human liver oxidative metabolism of O6-benzylguanine. Biochem Pharmacol 1995; 50:1385-9.

Roy U, Chakravarty G, Honer Zu Bentrup K, Mondal D. Montelukast is a potent and durable inhibitor of multidrug resistance protein 2-mediated efflux of taxol and saquinavir. Biol Pharm Bull 2009; 32:2002-9.

Roychowdhury S, McMullen MR, Pritchard MT, Li W, Salomon RG, Nagy LE. Formation of gamma-ketoaldehyde-protein adducts during ethanol-induced liver injury in mice. Free Radic Biol Med 2009; 47:1526-38.

Royer I, Monsarrat B, Sonnier M, Wright M, Cresteil T. Metabolism of docetaxel by human cytochromes P450: interactions with paclitaxel and other antineoplastic drugs. Cancer Res 1996; 56:58-65.

Roymans D, van Looveren C, Leone A et al. Determination of cytochrome P450 1A2 and cytochrome P450 3A4 induction in cryopreserved human hepatocytes. Biochem Pharmacol 2004; 67:427-37.

Royston MC, Mann D, Pickering-Brown S et al. Apolipoprotein E epsilon-2 allele promotes longevity and protects patients with Down’s syndrome from dementia. Neuroreport 1994; 5:2583-5.

Rozenfeld R, Reaux A, Iturrioz X et al. Aminopeptidase A, generating one of the main effector peptides of the brain renin-angiotensin system, angiotensin III, plays a key role in central control of blood pressure. Proc West Pharmacol Soc 2003; 46:39-44.

Rozycka A, Steinborn B, Trzeciak WH. The 1674+11C>T polymorphism of CHRNA4 is associated with juvenile myoclonic epilepsy. Seizure 2009; 18:601-3.

Ruaño G, Bernene J, Windemuth A et al. Physiogenomic comparison of edema and BMI in patients receiving rosiglitazone or pioglitazone. Clin Chim Acta 2009; 400:48-55.

Ruaño G, Goethe JW, Caley C et al. Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients. Mol Psychiatry 2007; 12:474-82.

Ruaño G, Thompson PD, Windemuth A et al. Physiogenomic association of statin-related myalgia to serotonin receptors. Muscle Nerve 2007; 36:329-35.

Rubin CM, Carrino JJ, Dickler MN, Leibowitz D, Smith SD, Westbrook CA. Heterogeneity of genomic fusion of BCR and ABL in Philadelphia chromosome-positive acute lymphoblastic leukemia. Proc Natl Acad Sci USA 1988; 85:2795-9.

Rubin D, Helwig U, Pfeuffer M et al. A common functional exon polymorphism in the microsomal triglyceride transfer protein gene is associated with type 2 diabetes, impaired glucose metabolism and insulin levels. J Hum Genet 2006; 51:567-74.

Rubin LA, Amos CI, Wade JA et al. Investigating the genetic basis for ankylosing spondylitis. Linkage studies with the major histocompatibility complex region. Arthritis Rheum 1994; 37:1212-20.

Rubini M, Brusati R, Garattini G et al. Cystathionine beta-synthase c. 844ins68 gene variant and non-syndromic cleft lip and palate. Am J Med Genet A 2005; 136:368-72.

Rubinow K, Snyder C, Amory J, Hoofnagle A, Page S. Acute testosterone deprivation reduces insulin sensitivity in men. Clin Endocrinol 2011. doi:10. 1111/j. 1365-2265. 2011. 04189. x.

Rubinsztein DC, Leggo J, Coles R et al. Phenotypic characterization of individuals with 30-40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36-39 repeats. Am J Hum Genet 1996; 59:16-22.

Rubinsztein DC, Leggo J, Chiano M et al. Genotypes at the GluR6 kainate receptor locus are associated with variation in the age of onset of Huntington disease. Proc Natl Acad Sci USA 1997; 94:3872-6.

Rubio-Cabezas O, Klupa T, Malecki MT; CEED3 Consortium. Permanent neonatal diabetes mellitus-the importance of diabetes differential diagnosis in neonates and infants. Eur J Clin Invest 2011; 41:323-33.

Rubio-Cabezas O, Regueras L, Muñoz-Calvo MT, Bartolomé M, Pozo J, Argente J. Primary hypoaldosteronism and moderate bilateral deafness in a child with a homozygous missense mutation (Thr318Met) in the CYP11B2 gene. An Pediatr 2010; 73:31-4.

Rubis B, Polrolniczak A, Knula H, Potapinska O, Kaczmarek M, Rybczynska M. Phytosterols in physiological concentrations target multidrug resistant cancer cells. Med Chem 2010; 6:184-90.

Ruchat SM, Elks CE, Loos RJ et al. Evidence of Interaction between Type 2 Diabetes Susceptibility Genes and Dietary Fat Intake for Adiposity and Glucose Homeostasis-Related Phenotypes. J Nutrigenet Nutrigenomics 2010; 2:225-34.

Ruchat SM, Rankinen T, Weisnagel SJ et al. Improvements in glucose homeostasis in response to regular exercise are influenced by the PPARG Pro12Ala variant: results from the HERITAGE Family Study. Diabetologia 2010; 53:679-89.

Rudberg I, Hendset M, Uthus LH, Molden E, Refsum H. Heterozygous mutation in CYP2C19 significantly increases the concentration/dose ratio of racemic citalopram and escitalopram (S-citalopram). Ther Drug Monit 2006; 28:102-5.

Rudberg I, Mohebi B, Hermann M, Refsum H, Molden E. Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients. Clin Pharmacol Ther 2008; 83:322-7.

Rudberg I, Reubsaet JL, Hermann M, Refsum H, Molden E. Identification of a novel CYP2C19-mediated metabolic pathway of S-citalopram in vitro. Drug Metab Dispos 2009; 37:2340-8.

Rudek MA, Zhao M, Smith NF et al. In vitro and in vivo clinical pharmacology of dimethyl benzoylphenylurea, a novel oral tubulin-interactive agent. Clin Cancer Res 2005; 11:8503-11.

Rudin CM, Liu W, Desai A et al. Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol 2008; 26:1119-27.

Rudolph A, Sainz J, Hein R et al. Modification of menopausal hormone therapy-associated colorectal cancer risk by polymorphisms in sex steroid signaling, metabolism and transport related genes. Endocr Relat Cancer 2011; 18:371-84.

Rueffert H, Thieme V, Wallenborn J et al. Do variations in the 5-HT3A and 5-HT3B serotonin receptor genes (HTR3A and HTR3B) influence the occurrence of postoperative vomiting? Anesth Analg 2009; 109:1442-7.

Ruhayel Y, Lundin K, Giwercman Y, Halldén C, Willén M, Giwercman A. Androgen receptor gene GGN and CAG polymorphisms among severely oligozoospermic and azoospermic Swedish men. Hum Reprod 2004; 19:2076-83.

Rühl R, Sczech R, Landes N, Pfluger P, Kluth D, Schweigert FJ. Carotenoids and their metabolites are naturally occurring activators of gene expression via the pregnane X receptor. Eur J Nutr 2004; 43:336-43.

Ruhnke M, Nussler AK, Ungefroren H et al. Human monocyte-derived neohepatocytes: a promising alternative to primary human hepatocytes for autologous cell therapy. Transplantation 2005; 79:1097-103.

Ruike Z, Junhua C, Wenxing P. In vitro and in vivo evaluation of the effects of duloxetine on P-gp function. Hum Psychopharmacol 2010; 25:553-9.

Ruiter R, Bijl MJ, van Schaik RH et al. CYP2C19*2 polymorphism is associated with increased survival in breast cancer patients using tamoxifen. Pharmacogenomics 2010; 11:1367-75.

Ruiz-Contreras AE, Delgado-Herrera M, García-Vaca PA et al. Involvement of the AATn polymorphism of the CNR1 gene in the efficiency of procedural learning in humans. Neurosci Lett 2011; 494:202-6.

Ruiz-Ferrer M, Fernández RM, Antinolo G, López-Alonso M, Eng C, Borrego S. A complex additive model of inheritance for Hirschsprung disease is supported by both RET mutations and predisposing RET haplotypes. Genet Med 2006; 8:704-10.

Rujescu D, Ingason A, Cichon S et al. Disruption of the neurexin 1 gene is associated with schizophrenia. Hum Mol Genet 2009; 18:988-96.

Rulcova A, Prokopova I, Krausova L et al. Stereoselective interactions of warfarin enantiomers with the pregnane X nuclear receptor in gene regulation of major drug-metabolizing cytochrome P450 enzymes. J Thromb Haemost 2010; 8:2708-17.

Rumsby G. Biochemical and genetic diagnosis of the primary hyperoxalurias: a review. Mol Urol 2000; 4:349-54.

Rumsby G. An overview of the role of genotyping in the diagnosis of the primary hyperoxalurias. Urol Res 2005; 33:318-20.

Rumsby G, Mandel H, Avey C, Geraerts A. Polymorphisms in the alanine:glyoxylate aminotransferase gene and their application to the prenatal diagnosis of primary hyperoxaluria type 1. Nephrol Dial Transplant 1995; 10 Suppl 8:30-2.

Rund D, Krichevsky S, Bar-Cohen S et al. Therapy-related leukemia: clinical characteristics and analysis of new molecular risk factors in 96 adult patients. Leukemia 2005; 19:1919-28.

Runge D, Köhler C, Kostrubsky VE et al. Induction of cytochrome P450 (CYP)1A1, CYP1A2, and CYP3A4 but not of CYP2C9, CYP2C19, multidrug resistance (MDR-1) and multidrug resistance associated protein (MRP-1) by prototypical inducers in human hepatocytes. Biochem Biophys Res Commun 2000; 273:333-41.

Rungroj N, Sritippayawan S, Thongnoppakhun W et al. Prothrombin haplotype associated with kidney stone disease in Northeastern Thai patients. Urology 2011; 77:249.

Runkel M, Bourian M, Tegtmeier M, Legrum W. The character of inhibition of the metabolism of 1,2-benzopyrone (coumarin) by grapefruit juice in human. Eur J Clin Pharmacol 1997; 53:265-9.

Runkel M, Tegtmeier M, Legrum W. Metabolic and analytical interactions of grapefruit juice and 1,2-benzopyrone (coumarin) in man. Eur J Clin Pharmacol 1996; 50:225-30.

Rushmore TH, Reider PJ, Slaughter D, Assang C, Shou M. Bioreactor systems in drug metabolism: synthesis of cytochrome P450-generated metabolites. Metab Eng 2000; 2:115-25.

Rusiecka I, Składanowski AC. Induction of the multixenobiotic/multidrug resistance system in various cell lines in response to perfluorinated carboxylic acids. Acta Biochim Pol 2008; 55:329-37.

Rusin M, Zajkowicz A, Butkiewicz D. Resveratrol induces senescence-like growth inhibition of U-2 OS cells associated with the instability of telomeric DNA and upregulation of BRCA1. Mech Ageing Dev 2009; 130:528-37.

Russcher H, Smit P, van den Akker EL et al. Two polymorphisms in the glucocorticoid receptor gene directly affect glucocorticoid-regulated gene expression. J Clin Endocrinol Metab 2005; 90:5804-10.

Russel FG, Koenderink JB, Masereeuw R. Multidrug resistance protein 4 (MRP4/ABCC4): a versatile efflux transporter for drugs and signalling molecules. Trends Pharmacol Sci 2008; 29:200-7.

Russell AI, Cunninghame Graham DS, Shepherd C et al. Polymorphism at the C-reactive protein locus influences gene expression and predisposes to systemic lupus erythematosus. Hum Mol Genet 2004; 13:137-47.

Russell T, Stoltz M, Weir S. Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers. Clin Pharmacol Ther 1998; 64:612-21.

Russo C, Schettini G, Saido TC et al. Presenilin-1 mutation in Alzheimer’s disease. Nature 2000; 405:531-2.

Russo L, Iafusco D, Brescianini S et al. Permanent diabetes during the first year of life: multiple gene screening in 54 patients. Diabetologia 2011; 54:1693-701.

Russo MT, de Luca G, Casorelli I et al. Role of MUTYH and MSH2 in the control of oxidative DNA damage, genetic instability, and tumorigenesis. Cancer Res 2009; 69:4372-9.

Rust S, Rosier M, Funke H et al. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat Genet 1999; 22:352-5.

Rüther U, Garber C, Komitowski D, Müller R, Wagner EF. Deregulated c-fos expression interferes with normal bone development in transgenic mice. Nature 1987; 325:412-6.

Rutherford K, Daggett V. Four human thiopurine s-methyltransferase alleles severely affect protein structure and dynamics. J Mol Biol 2008; 4:803-14.

Ruwende C, Hill A. Glucose-6-phosphate dehydrogenase deficiency and malaria. J Mol Med 1998; 76:581-8.

Ruwende C, Khoo SC, Snow RW et al. Natural selection of hemi- and heterozygotes for G6PD deficiency in Africa by resistance to severe malaria. Nature 1995; 376:246-9.

Ruzilawati AB, Gan SH. CYP3A4 genetic polymorphism influences repaglinide’s pharmacokinetics. Pharmacology 2010; 85:357-64.

Ruzilawati AB, Suhaimi AW, Gan SH. Genetic polymorphisms of CYP3A4: CYP3A4*18 allele is found in five healthy Malaysian subjects. Clin Chim Acta 2007; 383:158-62.

Ruzzo A, Graziano F, Kawakami K et al. Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy. J Clin Oncol 2006; 24:1883-91.

Rybakowski JK, Dmitrzak-Weglarz M, Suwalska A, Leszczynska-Rodziewicz A, Hauser J. Dopamine D1 receptor gene polymorphism is associated with prophylactic lithium response in bipolar disorder. Pharmacopsychiatry 2009; 42:20-2.

Rybalkin SD, Bornfeldt KE, Sonnenburg WK et al. Calmodulin-stimulated cyclic nucleotide phosphodiesterase (PDE1C) is induced in human arterial smooth muscle cells of the synthetic, proliferative phenotype. J Clin Invest 1997; 100:2611-21.

Ryckman KK, Morken NH, White MJ et al. Maternal and fetal genetic associations of PTGER3 and PON1 with preterm birth. PLoS One 2010. doi:10. 1371/journal. pone. 0009040.

Rydzanicz M, Golusinski P, Mielcarek-Kuchta D, Golusinski W, Szyfter K. Cyclin D1 gene (CCND1) polymorphism and the risk of squamous cell carcinoma of the larynx. Eur Arch Otorhinolaryngol 2006; 263:43-8.

Rytkonen EMK, Halila R, Laan M et al. The human gene for xanthine dehydrogenase (XDH) is localized on chromosome band 2p22. Cytogenet Cell Genet 1995; 68:61-3.

Ryu JY, Song IS, Sunwoo YE et al. Development of the “Inje cocktail” for high-throughput evaluation of five human cytochrome P450 isoforms in vivo. Clin Pharmacol Ther 2007; 82:531-40.

Rzuczek SG, Pilch DS, Liu A, Liu L, LaVoie EJ, Rice JE. Macrocyclic pyridyl polyoxazoles: selective RNA and DNA G-quadruplex ligands as antitumor agents. J Med Chem 2010; 53:3632-44.